• Abboud J, Ghaith GM, Gordon SC. Primary sclerosing cholangitis: a revised clinical spectrum. Am. J. Gastroenterol. 97: S103 (2002). *

• Abraham SC, Kamath PS, Eghtesad B, Demetris AJ, Krasinskas AM. Liver transplantation in precirrhotic biliary tract disease: portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am. J. Surg. Pathol. 30: 1454-1461 (2006).

• Abu-Hamda EM, Baron TH. Endoscopic management of cholangiocarcinoma. Semin. Liver Dis. 24: 165-175 (2004).

• Acevedo Ribo M, Moreno Planas JM, Sanz Moreno C, Rubio Gonzalez EE, Rubio Gonzalez E, Boullosa Grana E, Sanchez-Turrion V, Sanz Guajardo D, Cuervas-Mons V. Therapy of intractable pruritus with MARS. Transplant. Proc. 37: 1480-1481 (2005). *

• Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver. Annals of Gastroenterology 19: 146-151 (2006). *

• Affes N, Mseddi A, Feriani N, Beyrouti MI. Extrahepatic cholestasis secondary to Castleman's disease. Rev. Med. Interne. 30: 450-452 (2009).

• Aguilar-Bernier M, Bassas-Vila J, Sanz-Munoz C, Miranda-Romero A. Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. Br. J. Dermatol. 152: 808-809 (2005). *

• Ai Y, Liu SY, Yao Q. Clinical characteristics of 1241 cases of intrahepatic cholestasis of pregnancy. Zhonghua Fu Chan Ke Za Zhi 39: 217-220 (2004).

• Alagille D. Management of paucity of interlobular bile ducts. J. Hepatol. 1: 561-565 (1985).

• Alallam A, Barth D, Heathcote EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can. J. Gastroenterol. 22: 505-507 (2008). *

• Alarcon-Segovia D, Mayorga-Cortes A, Wolpert E. Primary biliary cirrhosis. Prompt relief of pruritus with azathioprine treatment. JAMA 214: 367-368 (1970).

• Alba LM, Angulo P, Lindor KD. Primary sclerosing cholangitis. Minerva Gastroenterol. Dietol. 48: 99-113 (2002).

• Alberti-Flor JJ, Avant GR, Dunn GD. Primary sclerosing cholangitis. South. Med. J. 78: 173-177 (1985).

• Alberti-Flor JJ, Jeffers L, Schiff ER. Primary sclerosing cholangitis occurring in a patient with systemic lupus erythematosus and diabetes mellitus. Am. J. Gastroenterol. 79: 889-891 (1984).

• Alburquerque Miranda M, Vargas Cardenas G, Lozano Miranda Z, Reyes Mugruza T, Li Torres W, Valdivia Roldan M. Recurrent benign intrahepatic cholestasis and their progression to familiar progressive intrahepatic cholestasis. Rev. Gastroenterol. Peru 28: 183-188 (2008).

• Aldersley MA, O'Grady JG. Hepatic disorders. Features and appropriate management. Drugs 49: 83-102 (1995).

• Almasio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 40 Suppl. 3: 111-123 (1990).

• Almasio PL, Floreani A, Chiaramonte M, Provenzano G, Battezzati P, Crosignani A, Podda M, Todros L, Rosina F, Saccoccio G, Manenti F, Ballardini G, Bianchi FP, Scheuer PJ, Davies SE, Craxi A. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Aliment. Pharmacol. Ther. 14: 1645-1652 (2000). *

• Alnounou M, Munoz SJ. Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf] Practical Gastroenterology April 2006: 92-100 (2006). *

• Altrichter S, Boodstein N, Maurer M. Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Allergy 64: 652-656 (2009). *

• Alvarez F. Treatments in chronic cholestasis in children. Ann. Nestle [Engl.] 66: 127-135 (2008).

• Amante MF, Filippini AV, Cejas N, Lendoire J, Imventarza O, Parisi C. Dress syndrome and fulminant hepatic failure induced by lamotrigine. Ann. Hepatol. 8: 75-77 (2009). *

• Amatya B, Nordlind K. Focus groups in Swedish psoriatic patients with pruritus. J. Dermatol. 35: 1-5 (2008).

• Amatya B, Nordlind K, Wahlgren CF. Responses to intradermal injections of substance P in psoriasis patients with pruritus. Skin Pharmacol. Physiol. 23: 133-138 (2009).

• Ambinder EP, Cohen LB, Wolke AM, Field SP, Adelsberg B, Schaffner F, Zaroulis CG. The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis. J. Clin. Apheresis 2: 219-223 (1985).

• Ambros-Rudolph CM, Glatz M, Trauner M, Kerl H, Mullegger RR. The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from Central Europe. Arch. Dermatol. 143: 757-762 (2007). *

• Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44 (2002).

• Angulo P, Lindor KD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Liver Dis. 3: 529-570 (1999). *

• Arai I, Takano N, Hashimoto Y, Futaki N, Sugimoto M, Takahashi N, Inoue T, Nakaike S. Prostanoid DP(1) receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur. J. Pharmacol. 505: 229-235 (2004). *

• Arat M, Idilman R, Soydan EA, Soykan I, Erden E, Karayalcin S, Akan H. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver. Clin. Transplant. 19: 798-803 (2005). *

• Arck P, Paus R. From the brain-skin connection: the neuroendocrine-immune misalliance of stress and itch. Neuroimmunomodulation 13: 347-356 (2006).

• Arican O. E-dermatology: emails about dermatological diseases on the internet. J. Dermatol. 34: 375-380 (2007). *

• Arrese M, Macias RI, Briz O, Perez MJ, Marin JJ. Molecular pathogenesis of intrahepatic cholestasis of pregnancy. Expert Rev. Mol. Med. 10: e9 (2008).

• Arrese M, Reyes H. Intrahepatic cholestasis of pregnancy: a past and present riddle. Ann. Hepatol. 5: 202-205 (2006). *

• Artantas S, Gul U, Kilic A, Guler S. Skin findings in thyroid diseases. Eur. J. Intern. Med. 20: 158-161 (2009).

• Aviles J, Macia M, Morales S, Perez F, Moreno A, Navarro J, Navazo L, Garcia J. Efficiency of dialysis with albumin in the treatment of patients with advanced hepatic insufficiency: initial experience with the MARS system in Spain. Nefrologia 21: 376-385 (2001).

• Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S. Clindamycin-induced acute cholestatic hepatitis. World J. Gastroenterol. 13: 5408-5410 (2007). *

• Aytac S, Kargili A, Turkay C. A prolonged gestational intrahepatic cholestasis: a case report. Turk. J. Gastroenterol. 17: 206-208 (2006). *

• Babatin MA, Sanai FM, Swain MG. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Aliment. Pharmacol. Ther. 24: 813-820 (2006). *

• Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1: 574-576 (1989).

• Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102: 2077-2080 (1992).

• Bacq Y, Gendrot C, Perrotin F, Lefrou L, Chretien S, Vie-Buret V, Brechot MC, Andres C. ABCB4 gene mutations and single nucleotide polymorphisms in women with intrahepatic cholestasis of pregnancy. J. Med. Genet. 46: 711-715 (2009).

• Bacq Y, Myara A, Brechot MC, Hamon C, Studer E, Trivin F, Metman EH. Serum conjugated bile acid profile during intrahepatic cholestasis of pregnancy. J. Hepatol. 22: 66-70 (1995). *

• Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 24: 573-589 (1997). *

• Balistreri WF. Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Ballmer-Weber BK, Dummer R. Pruritus in frequent skin diseases and therapeutic options. Schweiz. Rundsch. Med. Prax. 96: 107-111 (2007).

• Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *

• Baron TH, Fleischer DE. Past, present, and future of endoscopic retrograde cholangiopancreatography: perspectives on the National Institutes of Health consensus conference. Mayo Clin. Proc. 77: 407-412 (2002). *

• Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, Eskreis D, Katz S. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 10: 414-419 (1989).

• Batta AK, Salen G, Mirchandani R, Tint GS, Shefer S, Batta M, Abroon J, O'Brien CB, Senior JR. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 88: 691-700 (1993).

• Battezzati PM, Podda M, Bianchi FB, Naccarato R, Orlandi F, Surrenti C, Pagliaro L, Manenti F. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. J. Hepatol. 17: 332-338 (1993).

• Bedi MK. Successful treatment of long-standing, recalcitrant subcorneal pustular dermatosis with etanercept. Skinmed. 6: 245-247 (2007).

• Bellmann R, Graziadei IW, Feistritzer C, Schwaighofer H, Stellaard F, Sturm E, Wiedermann CJ, Joannidis M. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl. 10: 107-114 (2004). *

• Berg CL, Gollan JL. Primary biliary cirrhosis: new therapeutic directions. Scand. J. Gastroenterol. Suppl. 192: 43-49 (1992).

• Bergasa NV. Treatment of the pruritus of cholestasis: from unbearable lightness to substance. Hepatology 39: 1450-1453 (2004). *

• Bergasa NV. Pruritus in chronic liver disease: mechanisms and treatment. Curr. Gastroenterol. Rep. 6: 10-16 (2004).

• Bergasa NV. Hypothesis: taste disorders in patients with liver disease may be mediated in the brain: potential mechanisms for a central phenomenon. Am. J. Gastroenterol. 93: 1209-1210 (1998).

• Bergasa NV. An approach to the management of the pruritus of cholestasis. Clin. Liver Dis. 8: 55-66 (2004).

• Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin. Liver Dis. 12: 385-406 (2008).

• Bergasa NV. Management of complications of cholestasis: pruritus, fatigue and bone disease. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 54. October 15-16 (2003). *

• Bergasa NV. The pruritus of cholestasis. J. Hepatol. 43: 1078-1088 (2005). *

• Bergasa NV. Treatment of the pruritus of cholestasis. Curr. Treat. Options Gastroenterol. 7: 501-508 (2004).

• Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin. Liver Dis. 7: 879-900 (2003).

• Bergasa NV. Studying pruritus in the 21st century. Clin. Gastroenterol. Hepatol. 1: 249-251 (2003). *

• Bergasa NV. The pruritus of cholestasis. Semin. Dermatol. 14: 302-312 (1995).

• Bergasa NV. Update on the treatment of the pruritus of cholestasis. Clin. Liver Dis. 12: 219-234 (2008).

• Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, Schmitt JM, Walker EC, Jones EA. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann. Intern. Med. 123: 161-167 (1995). *

• Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J. Am. Acad. Dermatol. 41: 431-434 (1999).

• Bergasa NV, Jones A, Kleiner DE, Rabin L, Park Y, Wells MC, Hoofnagle JH. Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis. Am. J. Gastroenterol. 91: 295-299 (1996).

• Bergasa NV, Jones EA. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 108: 1582-1588 (1995). *

• Bergasa NV, Jones EA. The pruritus of cholestasis: evolving pathogenic concepts suggest new therapeutic options. Clin. Liver Dis. 2: 391-405, x (1998).

• Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, McGee M. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am. J. Gastroenterol. 96: 1563-1570 (2001). *

• Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020 (2004). *

• Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology 44: 1317-1323 (2006). *

• Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract. Res. Clin. Gastroenterol. 14: 643-655 (2000).

• Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, Jones EA. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 27: 679-684 (1998). *

• Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, Korenman JC, Park Y, Hoofnagle JH, Jones EA. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 102: 544-549 (1992).

• Bergquist A, Said K, Broome U. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand. J. Gastroenterol. 42: 88-93 (2007). *

• Bernacchi E, Amato L, Parodi A, Cottoni F, Rubegni P, De Pita O, Papini M, Rebora A, Bombardieri S, Fabbri P. Sjogren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin. Exp. Rheumatol. 22: 55-62 (2004).

• Bernuau J. Hepatic complications of pregnancy. Rev. Prat. 53: 1889-1893 (2003).

• Berr F. Do increased serum bile acids induce pruritus? Internist (Berl.) 32: 619-620 (1991).

• Berth-Jones J, Graham-Brown RA. Cholinergic pruritus, erythema and urticaria: a disease spectrum responding to danazol. Br. J. Dermatol. 121: 235-237 (1989).

• Berti S, Amato L, Chiarini C, Fabbri P. Case study: an itching and excoriated dermatosis during intrahepatic cholestasis of pregnancy. Skinmed. 4: 248-249 (2005).

• Bertolotti M, Ferrari A, Vitale G, Stefani M, Trenti T, Loria P, Carubbi F, Carulli N, Sternieri E. Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J. Hepatol. 27: 505-511 (1997). *

• Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 318-328 (2006). *

• Beuers U, Gerken G, Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 44: 280-281 (2006). *

• Beuers U, Oswald M. Cholestasis: therapeutic options. Ther. Umsch. 55: 97-103 (1998).

• Beyens MN, Guy C, Ollagnier M. Adverse effects of quinine in the treatment of leg cramps. Therapie 54: 59-62 (1999).

• Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 95: 2338-2342 (2000). *

• Bianchi FB, Muratori L. Primary and secondary autoimmunity in hepatology. Ann. Ital. Med. Int. 15: 56-62 (2000).

• Bigliardi PL, Stammer H, Jost G, Rufli T, Buchner S, Bigliardi-Qi M. Treatment of pruritus with topically applied opiate receptor antagonist. J. Am. Acad. Dermatol. 56: 979-988 (2007).

• Bilac C, Ermertcan AT, Bilac DB, Deveci A, Horasan GD. The relationship between symptoms and patient characteristics among psoriasis patients. Indian J. Dermatol. Venereol. Leprol. 75: 551 (2009). *

• Binder T, Salaj P, Zima T, Vitek L. Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP). Ceska. Gynekol. 71: 92-98 (2006).

• Binder T, Salaj P, Zima T, Vitek L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J. Perinat. Med. 34: 383-391 (2006).

• Binder T, Zima T, Vítek L. Biochemical parameters of the intrahepatic cholestasis of pregnancy. Ceska. Gynekol. 72: 90-94 (2007).

• Bircher AJ. Water-induced itching. Dermatologica 181: 83-87 (1990).

• Bircher AJ, Meier-Ruge W. Aquagenic pruritus. Water-induced activation of acetylcholinesterase. Arch. Dermatol. 124: 84-89 (1988).

• Biro T, Ko MC, Bromm B, Wei ET, Bigliardi P, Siebenhaar F, Hashizume H, Misery L, Bergasa NV, Kamei C, Schouenborg J, Roostermann D, Szabo T, Maurer M, Bigliardi-Qi M, Meingassner JG, Hossen MA, Schmelz M, Steinhoff M. How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp. Dermatol. 14: 225-240 (2005). *

• Biro T, Toth BI, Marincsak R, Dobrosi N, Geczy T, Paus R. TRP channels as novel players in the pathogenesis and therapy of itch. Biochim. Biophys. Acta 1772: 1004-1021 (2007). *

• Bissonnette R, Nigen S, Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. J. Cutan. Med. Surg. 12: 230-234 (2008).

• Blejter J, Weller S, Pace R, Cusumano H, Giambini D. Autoimmune pancreatitis: an adolescent case and review of literature. J. Pediatr. Surg. 43: 1368-1372 (2008).

• Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann. Intern. Med. 82: 310-317 (1975).

• Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broome U, Chapman R, Fausa O, Egeland T, Rocca G, Schrumpf E. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand. J. Gastroenterol. 37: 1205-1211 (2002). *

• Boberg KM, Schrumpf E. Diagnosis and treatment of cholangiocarcinoma. Curr. Gastroenterol. Rep. 6: 52-59 (2004).

• Boberg KM, Schrumpf E. Diagnosis and differential diagnosis of primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 59-60. October 15-16 (2003). *

• Bock HH, Lammert F. Nuclear xeno-sensors as receptors for cholestatic bile acids: the second line of defense. Hepatology 35: 232-234 (2002). *

• Bohm M, Luger TA. Lichen planus responding to efalizumab. J. Am. Acad. Dermatol. 56: S92-S93 (2007).

• Boner AL, Peroni D, Bodini A, Delaini G, Piacentini G. Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Int. J. Immunopathol. Pharmacol. 20: 847-849 (2007).

• Bourke B, Goggin N, Walsh D, Kennedy S, Setchell KD, Drumm B. Byler-like familial cholestasis in an extended kindred. Arch. Dis. Child. 75: 223-227 (1996).

• Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129: 735-740 (2005). *

• Brajac I, Kastelan M, Prpic-Massari L, Perisa D, Loncarek K, Malnar D. Melanocyte as a possible key cell in the pathogenesis of psoriasis vulgaris. Med. Hypotheses 73: 254-246 (2009).

• Bremmer M, Driscoll MS, Colgan R. The skin disorders of pregnancy: a family physician's guide. J. Fam. Pract. 59: 89-96 (2010).

• Brigman C, Feranchak A. Liver involvement in cystic fibrosis. Curr. Treat. Options Gastroenterol. 9: 484-496 (2006).

• Brites D. Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. Ann. Hepatol. 1: 20-28 (2002). *

• Brites D, Rodrigues CM, Oliveira N, Cardoso M, Graca LM. Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. J. Hepatol. 28: 91-98 (1998). *

• Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 98: 2736-2741 (2003). *

• Brunner W. Pruritus - also a challenge in internal medicine. Schweiz. Med. Wochenschr. 125: 2244-2250 (1995).

• Burrows RF, Clavisi O, Burrows E. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst. Rev. 4: CD000493 (2001). *

• Bustorff-Silva J, Neto LS, Olimpio H, de Alcantara RV, Matsushima E, De Tommaso AM, Brandao MA, Hessel G. Partial internal biliary diversion through a cholecystojejunocolonic anastomosis-a novel surgical approach for patients with progressive familial intrahepatic cholestasis: a preliminary report. J. Pediatr. Surg. 42: 1337-1340 (2007).

• Caballeria L, Pares A, Rodes J. Treatment of primary biliary cirrhosis. Contributions to Science 1: 79-85 (1999). *

• Cafardi JA, Cantrell W, Wang W, Elmets CA, Elewski BE. The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis. Skinmed. 7: 67-72 (2008). *

• Caldwell SH, Leung PS, Spivey JR, Prindiville T, de Medina M, Saicheur T, Rowley M, Reddy KR, Coppel R, Jeffers LJ, et al. Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology 16: 899-905 (1992).

• Calmelet P, Coumaros D, Viville B, Raiga J, Favreau JJ, Treisser A. Ursodeoxycholic acid: prospect for treatment of gravidic cholestasis? Report of 3 cases. J. Gynecol. Obstet. Biol. Reprod. (Paris) 27: 617-621 (1998).

• Calmus Y, Poupon R. Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases. Biochimie 73: 1335-1338 (1991).

• Cancado EL, Leitao RM, Carrilho FJ, Laudanna AA. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am. J. Gastroenterol. 93: 1510-1517 (1998). *

• Caramella C, Avouac J, Sogni P, Puechal X, Kahan A, Allanore Y. Association between rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine 74: 279-281 (2007). *

• Cardona J, Houssin D, Gauthier F, Devictor D, Losay J, Hadchouel M, Bernard O. Liver transplantation in children with Alagille syndrome - a study of twelve cases. Transplantation 60: 339-342 (1995).

• Carlton VE, Knisely AS, Freimer NB. Mapping of a locus for progressive familial intrahepatic cholestasis (Byler disease) to 18q21-q22, the benign recurrent intrahepatic cholestasis region. Hum. Mol. Genet. 4: 1049-1053 (1995).

• Carroll CL, Lang W, Snively B, Feldman SR, Callen J, Jorizzo JL. Development and validation of the Dermatomyositis Skin Severity Index. Br. J. Dermatol. 158: 345-350 (2008).

• Carson HJ, Cook BA. Mast cell tryptase in a case of anaphylaxis due to repeat antibiotic exposure. Leg. Med. (Tokyo) 11: 234-236 (2009).

• Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int. J. Immunopathol. Pharmacol. 19: 237-240 (2006).

• Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study). Int. J. Immunopathol. Pharmacol. 19: 225-229 (2006).

• Castano G, Fernandez L, Mas R, Illnait J, Mesa M, Fernandez JC. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin. Drug Investig. 23: 639-650 (2003).

• Cerio R, Murphy GM, Sladen GE, MacDonald DM. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br. J. Dermatol. 116: 265-267 (1987).

• Chamouard P, Walter P, Baumann R, Poupon R. Prolonged cholestasis associated with short-term use of celecoxib. Gastroenterol. Clin. Biol. 29: 1286-1288 (2005).

• Chan CW, Gunsar F, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, Burroughs AK. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment. Pharmacol. Ther. 21: 217-226 (2005). *

• Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br. J. Dermatol. 156: 1272-1277 (2007). *

• Chang Y, Golkar L. The use of naltrexone in the management of severe generalized pruritus in biliary atresia: report of a case. Pediatr. Dermatol. 25: 403-404 (2008).

• Chapman RW. The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17 (2003).

• Chazouilleres O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, Couzigou P, Labayle D, Trinchet JC. Ursodeoxycholic acid for primary sclerosing cholangitis. J. Hepatol. 11: 120-123 (1990).

• Chen J, Raymond K. Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml) (2006). *

• Chen YH, Lee MF, Tsai JJ, Wu HJ, Hwang GY. Specific IgE and IgG responses and cytokine profile in subjects with allergic reactions to biting midge Forcipomyia taiwana. Int. Arch. Allergy Immunol. 150: 66-74 (2009).

• Cheng HM, Hsiang CY, Chen GW, Wu SL, Chen JC, Huang CY, Bau DT, Ho TY. Inhibition of lipopolysaccharide-induced interleukin-1beta and tumor necrosis factor-alpha production by menthone through nuclear factor-kappaB signaling pathway in HaCat cells. Chin. J. Physiol. 51: 160-166 (2008).

• Chernev K, Bakalov V. Clinical-dispensary finding of patients with primary biliary cirrhosis. Vutr. Boles. 24: 42-46 (1985).

• Chhetri D, Gupta R, Duseja A, Dhiman RK, Chawla Y, Das A. Benign recurrent intrahepatic cholestasis (BRIC) in an adult. Trop. Gastroenterol. 28: 186-187 (2007).

• Chitturi S, Farrell GC. Drug-induced liver disease. Curr. Treat. Options Gastroenterol. 3: 457-462 (2000).

• Chitturi S, Farrell GC. Drug-induced cholestasis. Semin. Gastrointest. Dis. 12: 113-124 (2001).

• Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, Lee YJ, Jung SH, Kim AN, Cha SW. Acute drug-induced hepatitis caused by albendazole. J. Korean Med. Sci. 23: 903-905 (2008).

• Chon CY, Park JY. Primary biliary cirrhosis. Korean J. Hepatol. 12: 364-372 (2006).

• Christensen E, Crowe J, Doniach D, Popper H, Ranek L, Rodes J, Tygstrup N, Williams R. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78: 236-246 (1980).

• Christensen KL, Andersen BN, Vilstrup H. Primary sclerosing cholangitis with itching treated during pregnancy with ursodeoxycholic acid. Ugeskr. Laeger. 159: 7151-7153 (1997).

• Cicek D, Kandi B, Demir B, Turgut D. Intrahepatic cholestasis occurring with prurigo of pregnancy. Skinmed. 6: 298-301 (2007). *

• Cies JJ, Giamalis JN. Treatment of cholestatic pruritus in children. Am. J. Health Syst. Pharm. 64: 1157-1162 (2007). *

• Clark LN, Lebwohl M. Recent advances in medical dermatology. Int. J. Dermatol. 46: 1005-1010 (2007). *

• Cohen AD, Van-Dijk D, Naggan L, Vardy DA. Factor analysis of the Beer Sheva Psoriasis Severity Score (BPSS). Isr. Med. Assoc. J. 10: 419-423 (2008). *

• Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 26: 291-294 (1985). *

• Cohran VC, Heubi JE. Treatment of pediatric cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 403-415 (2003).

• Colombo C, Crosignani A, Apostolo MG, Marzano MT, Bettinardi N, Giunta A. Oral bile acids in cystic fibrosis-associated liver disease. J. R. Soc. Med. 87 Suppl. 21: 20-24 (1994). *

• Coltorti M, Bortolini M, Di Padova C. A review of the studies on the clinical use of S-adenosylmethionine (SAMe) for the symptomatic treatment of intrahepatic cholestasis. Methods Find. Exp. Clin. Pharmacol. 12: 69-78 (1990).

• Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, Eigenbrodt EH, Munoz SJ, Rubin R, Garcia-Tsao G, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22: 759-766 (1995).

• Combes B, Luketic VA, Peters MG, Zetterman RK, Garcia-Tsao G, Munoz SJ, Lin D, Flye N, Carithers RL Jr. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am. J. Gastroenterol. 99: 264-268 (2004). *

• Connolly CS, Kantor GR, Menduke H. Hepatobiliary pruritus: what are effective treatments? J. Am. Acad. Dermatol. 33: 801-805 (1995).

• Connolly MK. Sjogren's syndrome. Semin. Cutan. Med. Surg. 20: 46-52 (2001).

• Conrad R, Geiser F, Haidl G, Hutmacher M, Liedtke R, Wermter F. Relationship between anger and pruritus perception in patients with chronic idiopathic urticaria and psoriasis. J. Eur. Acad. Dermatol. Venereol. 22: 1062-1069 (2008). *

• Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H(4) receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J. Invest. Dermatol. Nov 12 [Epub ahead of print] (2009). *

• Crippa G, Cagnoni C, Castelli A, Concesi C, Girometta S, Pancotti D, Sverzellati E, Tacchini G, Pierfranceschi MG, Carrara GC. Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis. Clin. Ter. 146: 367-372 (1995).

• Crippin JS. Liver transplantation for cholestatic liver disease: screening and assessment of risk factors. Liver Transpl. Surg. 4: S2-S8 (1998).

• Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J. Gastroenterol. 14: 3313-3327 (2008). *

• Cross TJ, Berry PA, Akbar N, Wendon J, Thein SL, Harrison PM. Sickle liver disease - an unusual presentation in a compound heterozygote for HbS and a novel beta-thalassemia mutation. Am. J. Hematol. 82: 852-854 (2007). *

• Crowe J, Christensen E, Doniach D, Popper H, Tygstrup N, Williams R. Early features of primary biliary cirrhosis: an analysis of 85 patients. Am. J. Gastroenterol. 80: 466-468 (1985).

• Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. Semin. Liver Dis. 26: 52-61 (2006). *

• Cynamon HA, Andres JM, Iafrate RP. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology 98: 1013-1016 (1990).

• Czaja AJ. Autoimmune hepatitis - approach to diagnosis. MedGenMed. 8: 55 (2006). *

• Dahlan Y, Smith L, Simmonds D, Jewell LD, Wanless I, Heathcote EJ, Bain VG. Pediatric-onset primary biliary cirrhosis. Gastroenterology 125: 1476-1479 (2003). *

• Dahms BB. Hepatoma in familial cholestatic cirrhosis of childhood: its occurrence in twin brothers. Arch. Pathol. Lab. Med. 103: 30-33 (1979).

• Dall M. Plasmapheresis in the treatment of cholestasis-induced pruritus. Ugeskr. Laeger. 168: 779-781 (2006).

• Daly BM, Shuster S. Antipruritic action of thalidomide. Acta Derm. Venereol. 80: 24-25 (2000).

• Dann AT, Kenyon AP, Seed PT, Poston L, Shennan AH, Tribe RM. Glutathione S-transferase and liver function in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology 40: 1406-1414 (2004). *

• Dann AT, Kenyon AP, Wierzbicki AS, Seed PT, Shennan AH, Tribe RM. Plasma lipid profiles of women with intrahepatic cholestasis of pregnancy. Obstet. Gynecol. 107: 106-114 (2006).

• Dantas W. Primary sclerosing cholangitis. Rev. Gastroenterol. Peru 20: 270-284 (2000).

• Dash A, Kragel P. Primary biliary cirrhosis in an elderly man with normal liver tests. South. Med. J. 102: 1272-1274 (2009).

• Davies MH, da Silva RC, Jones SR, Weaver JB, Elias E. Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid. Gut 37: 580-584 (1995). *

• Davis M. Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. Clin. Pharmacokinet. 46: 825-850 (2007).

• Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J. Rare Dis. 4: 1 (2009). *

• Day C, Hewins P, Sheikh L, Kilby M, McPake D, Lipkin G. Cholestasis in pregnancy associated with ciclosporin therapy in renal transplant recipients. Transpl. Int. 19: 1026-1029 (2006). *

• de la Portilla F, Fernandez A, Leon E, Rada R, Cisneros N, Maldonado VH, Vega J, Espinosa E. Evaluation of the use of PTQ(TM) implants for the treatment of incontinent patients due to internal anal sphincter dysfunction. Colorectal Dis. 10: 89-94 (2008). *

• de Pagter AG, van Berge Henegouwen GP, ten Bokkel Huinink JA, Brandt KH. Familial benign recurrent intrahepatic cholestasis. Interrelation with intrahepatic cholestasis of pregnancy and from oral contraceptives? Gastroenterology 71: 202-207 (1976).

• Degos F, Degott C, Erlinger S. Ineffectiveness of corticosteroids in cholestatic forms of chronic active hepatitis. Gastroenterol. Clin. Biol. 4: 246-250 (1980).

• Delle Monache M, Salvio A, Fiocca F, Basoli A, Ricci GL. Primary sclerosing cholangitis: an analysis of 37 retrospective cases. Ital. J. Gastroenterol. 24: 485-488 (1992).

• den Dulk M, Valentijn RM, Welten CA, Beyer GP. Intrahepatic cholestasis of pregnancy. Neth. J. Med. 60: 366-369 (2002). *

• Der G, Love T, Schreck J, Horn M. Primary sclerosing cholangitis: a case presentation. Gastroenterol. Nurs. 28: 13-16 (2005). *

• Dhiman RK, Behera A, Chawla YK, Dilawari JB, Suri S. Portal hypertensive biliopathy. Gut 56: 1001-1008 (2007). *

• Dia D, Ba-Fall K, Bouldouyre M, Chevalier B, Debonne JM. DRESS syndrome to allopurinol: a case in Dakar. Dakar Med. 49: 114-115 (2004).

• Diaferia A, Nicastri PL, Tartagni M, Loizzi P, Iacovizzi C, Di Leo A. Ursodeoxycholic acid therapy in pregnant women with cholestasis. Int. J. Gynaecol. Obstet. 52: 133-140 (1996).

• Dibble JB, Sheridan P, Losowsky MS. A survey of vitamin D deficiency in gastrointestinal and liver disorders. Q. J. Med. 53: 119-134 (1984).

• Diehl C, Lipozencic J, Ledic-Drvar D. The basis of topical superoxide dismutase antipruritic activity. Acta Dermatovenerol. Croat. 17: 25-39 (2009).

• Ding YL, Tan LL, Deng W. Clinical analysis of intrahepatic cholestasis during pregnancy in 150 patients. Hunan Yi Ke Da Xue Xue Bao 28: 645-647 (2003).

• Dinler G, Kocak N, Ozen H, Yuce A, Gurakan F. Ursodeoxycholic acid treatment in children with Byler disease. Pediatr. Int. 41: 662-665 (1999).

• Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H. Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk. J. Pediatr. 41: 91-98 (1999).

• Dominguez Ortega J, Trindade C, Alonso Llamazares A, Castellano Bravo A, Cimarra Alvarez-Lovel M, Martinez-Cocera C. Hypersensitivity to allopurinol. Efficacy of a desensitizing protocol in 3 cases. An. Med. Interna. 18: 27-28 (2001).

• Doria C, Doyle HR, Mandala L, Marino IR, Caruana G, Gruttadauria S, Lauro A, Magnone M, Scotti Foglieni C, Lamonaca V, Scott VL. Changes in serum electrolytes during treatment of patients in liver failure with molecular adsorbent recirculating system. Int. J. Artif. Organs 26: 918-923 (2003).

• Douglass HO Jr. Idiopathic sclerosing cholangitis. Pathophysiologic observations. Am. J. Surg. 130: 82-87 (1975).

• Dreno B, Blouin E, Moyse D. Lithium gluconate 8% in the treatment of seborrheic dermatitis. Ann. Dermatol. Venereol. 134: 347-351 (2007).

• Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).

• Duclos-Vallee JC, Hadengue A, Ganne-Carrie N, Robin E, Degott C, Erlinger S. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A. Dig. Dis. Sci. 40: 1069-1073 (1995).

• Duseja A, Chawla YK. What is rifampicin doing in pruritus of cholestasis? Trop. Gastroenterol. 22: 123-124 (2001).

• Ebrahimkhani MR, Moezi L, Kiani S, Merat S, Dehpour AR. Opioid receptor blockade improves mesenteric responsiveness in biliary cirrhosis. Dig. Dis. Sci. 53: 3007-3011 (2008). *

• Eckstein RP, Dowsett JF, Lunzer MR. Flucloxacillin induced liver disease: histopathological findings at biopsy and autopsy. Pathology 25: 223-228 (1993).

• Ee HL, Liu L, Goh CL, McGrath JA. Clinical and molecular dilemmas in the diagnosis of familial epidermolysis bullosa pruriginosa. J. Am. Acad. Dermatol. 56: S77-S81 (2007).

• Ekinci S, Karnak I, Gurakan F, Yuce A, Senocak ME, Cahit Tanyel F, Buyukpamukcu N. Partial external biliary diversion for the treatment of intractable pruritus in children with progressive familial intrahepatic cholestasis: report of two cases. Surg. Today 38: 726-730 (2008).

• El-Bitar MK, Muwakkit SA, Abboud MR, Sawaya RA, Boustany RM. Morvan syndrome following B-cell lymphoma. J. Child. Neurol. Jan 28 [Epub ahead of print] (2010).

• El-Karaksy H, Mansour S, El-Sayed R, El-Raziky M, El-Koofy N, Taha G. Safety and efficacy of rifampicin in children with cholestatic pruritus. Indian J. Pediatr. 74: 279-281 (2007). *

• Elias E. Hepatology highlights. Hepatology 42: 1241-1242 (2005). *

• Emond JC, Whitington PF. Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease). J. Pediatr. Surg. 30: 1635-1641 (1995).

• Engelmann G, Schmidt J, Oh J, Lenhartz H, Wenning D, Teufel U, Buchler MW, Hoffmann GF, Meyburg J. Indications for pediatric liver transplantation. Data from the Heidelberg pediatric liver transplantation program. Nephrol. Dial. Transplant. 22 Suppl. 8: viii23-viii28 (2007). *

• Englert C, Grabhorn E, Richter A, Rogiers X, Burdelski M, Ganschow R. Liver transplantation in children with progressive familial intrahepatic cholestasis. Transplantation 84: 1361-1363 (2007).

• Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig. Dis. Sci. 49: 1-4 (2004). *

• Erickson JM, Mawson AR. Possible role of endogenous retinoid (vitamin A) toxicity in the pathophysiology of primary biliary cirrhosis. J. Theor. Biol. 206: 47-54 (2000). *

• Ertekin V, Selimoglu MA, Orbak Z. An unusual combination of relapsing and cholestatic hepatitis A in childhood. Yonsei. Med. J. 44: 939-942 (2003). *

• Esber EJ, Ferguson DR. Primary sclerosing cholangitis. Gastroenterologist 2: 131-146 (1994).

• European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J. Hepatol. 51: 237-267 (2009). *

• Evans J, Zerpa H, Nuttall L, Boss M, Sherlock S. Copper chelation therapy in intrahepatic cholestasis of childhood. Gut 24: 42-48 (1983). *

• Everson GT. Liver problems in pregnancy: part 2 - managing pre-existing and pregnancy-induced liver disease. Medscape Womens Health 3: 2 (1998).

• Fagan EA. Intrahepatic cholestasis of pregnancy. Clin. Liver Dis. 3: 603-632 (1999).

• Fahey S. The experience of women with primary biliary cirrhosis: a literature review. J. Adv. Nurs. 30: 506-512 (1999).

• Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin: cutaneous disorders in the elderly. Am. J. Clin. Dermatol. 10: 73-86 (2009).

• Farmer JA, Gotto AM Jr. Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin. Endocrinol. Metab. 9: 825-847 (1995).

• Fasano MB. Dermatologic food allergy. Pediatr. Ann. 35: 727-731 (2006).

• Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin. Liver Dis. 11: 31-39 (1991).

• Favre N, Abergel A, Blanc P, Sapin V, Roszyk L, Gallot D. Unusual presentation of severe intrahepatic cholestasis of pregnancy leading to fetal death. Obstet. Gynecol. 114: 491-493 (2009).

• Feldman SR, Koo JY, Johnson LA, Preston NJ. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis 84: S25-S32 (2009).

• Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am. J. Gastroenterol. 93: 459-460 (1998).

• Ferry GD, Kirschner BS, Grand RJ, Issenman RM, Griffiths AM, Vanderhoof JA, Fiedorek SC, Winter HS, Hassall EG, Watkins JB, et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J. Pediatr. Gastroenterol. Nutr. 17: 32-38 (1993).

• Fitzgerald DA, Heagerty AH, Stephens M, Smith AG. Follicular toxic pustuloderma associated with allopurinol. Clin. Exp. Dermatol. 19: 243-245 (1994).

• Fleig WE, Laudage G, Sommer H, Wellmann W, Stange EF, Riemann J. Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis. Digestion 40: 173-180 (1988).

• Fleischer AB, Abramovits W, Breneman D, Jaracz E. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J. Dermatolog. Treat. 18: 151-157 (2007).

• Floreani A, Carderi I, Variola A, Rizzotto ER, Nicol J, Bergasa NV. A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus. Hepatology 43: 1152-1154 (2006). *

• Floreani A, Paternoster D, Melis A, Grella PV. S-Adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 67: 109-113 (1996).

• Floreani A, Zappala F, Mazzetto M, Naccarato R, Plebani M, Chiaramonte M. Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease. Dig. Dis. Sci. 39: 9-14 (1994).

• Fong DG, Angulo P, Burgart LJ, Lindor KD. Cetirizine-induced cholestasis. J. Clin. Gastroenterol. 31: 250-253 (2000).

• Franco J. Pruritus. Curr. Treat. Options Gastroenterol. 2: 451-456 (1999).

• Franco J, Saeian K. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101 (1999).

• Frederiksen SL, Chen W. D-penicillamine for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2: CD004182 (2004). *

• Frezza M. A meta-analysis of therapeutic trials with ademetionine in the treatment of intrahepatic cholestasis. Ann. Ital. Med. Int. 8 Suppl.: 48S-51S (1993).

• Frezza M, Pozzato G, Chiesa L, Stramentinoli G, di Padova C. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. Hepatology 4: 274-278 (1984).

• Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study. Gastroenterology 99: 211-215 (1990).

• Frezza M, Terpin MM, Peri A. S-Adenosyl-L-methionine (SAMe) and its use in hepatology. Minerva Gastroenterol. Dietol. 38: 145-151 (1992).

• Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann. Intern. Med. 116: 624-629 (1992).

• Friedman A, Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin. J. Am. Soc. Nephrol. 1: 182-192 (2006). *

• Friedman JD, Dello Buono FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann. Pharmacother. 35: 85-91 (2001).

• Gaj F, Crispino P. Proctological surgery: advantages derived from the use of an innovative detergent in the post-operative period. Clin. Ter. 160: 211-213 (2009).

• Garcia MA, Margarita R, Mirta C, Hugo C, Pablo L, Estela A, de Davila MT. Alagille syndrome: cutaneous manifestations in 38 children. Pediatr. Dermatol. 22: 11-14 (2005).

• Garcia Villarreal L, Zozaya JM, Macias E, Garcia Gonzalez N, Quiroga J, Conchillo F, Prieto J. The treatment of primary biliary cirrhosis with ursodeoxycholic acid. The short- and median-term results and their relation to the study of the disease. Rev. Esp. Enferm. Dig. 80: 311-315 (1991).

• Garioud A, Seksik P, Chretien Y, Corphechot C, Poupon R, Poupon RE, Chazouilleres O. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur. J. Gastroenterol. Hepatol. Sep 22 [Epub ahead of print] (2009). *

• Gaspari R, Cavaliere F, Sollazzi L, Perilli V, Melchionda I, Agnes S, Gasbarrini A, Avolio AW. Molecular adsorbent recirculating system (MARS) in patients with primary nonfunction and other causes of graft dysfunction after liver transplantation in the era of extended criteria donor organs. Transplant. Proc. 41: 253-258 (2009). *

• Gauthier-Villars M, Franchi S, Gauthier F, Fabre M, Pariente D, Bernard O. Cholestasis in children with portal vein obstruction. J. Pediatr. 146: 568-573 (2005). *

• Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J. Gastroenterol. 15: 2049-2066 (2009). *

• Gerson LB, Triadafilopoulos G. Palliative care in inflammatory bowel disease: an evidence-based approach. Inflamm. Bowel Dis. 6: 228-243 (2000). *

• Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 94: 488-493 (1988).

• Ghosn SH, Kibbi AG. Cutaneous manifestations of liver diseases. Clin. Dermatol. 26: 274-282 (2008).

• Giannakos G, Papanicolaou X, Trafalis D, Michaelidis I, Margaritis G, Christofilakis C. Stauffer's syndrome variant associated with renal cell carcinoma. Int. J. Urol. 12: 757-759 (2005).

• Gillespie DA, Vickers CR. Pruritus and cholestasis: therapeutic options. J. Gastroenterol. Hepatol. 8: 168-173 (1993).

• Ginsberg GG, Goodman ZD, Lewis JH. A 22-year-old man with thyroid cancer and cholestatic liver disease. Semin. Liver Dis. 11: 64-71 (1991).

• Gislason D, Bjoernsson E, Gislason T. Allergy and intolerance to food in an Icelandic urban population 20-44 years of age. Laeknabladid. 86: 851-857 (2000).

• Gittlen SD, Schulman ES, Maddrey WC. Raised histamine concentrations in chronic cholestatic liver disease. Gut 31: 96-99 (1990). *

• Glantz A, Benthin L, Lammert F, Mattsson LA, Marschall HU. Disulfated progesterone metabolites in urine relate to pruritus in intrahepatic cholestasis of pregnancy treated with ursodeoxycholic acid. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 62 (2006). *

• Glantz A, Lammert FL, Mattsson L-A, Marschall H-U. Intrahepatic cholestasis of pregnancy: results from the Swedish observation and intervention trials. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 79. June 18-19 (2004). *

• Glantz A, Marschall HU, Lammert F, Mattsson LA. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 42: 1399-1405 (2005). *

• Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology 40: 467-474 (2004). *

• Glantz A, Reilly SJ, Benthin L, Lammert F, Mattsson LA, Marschall HU. Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology 47: 544-551 (2008). *

• Glasova H, Beuers U. Extrahepatic manifestations of cholestasis. J. Gastroenterol. Hepatol. 17: 938-948 (2002). *

• Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 1: CD000551 (2002). *

• Goffe B, Papp K, Gratton D, Krueger GG, Darif M, Lee S, Bozic C, Sweetser MT, Ticho B. An integrated analysis of thirteen trials summarizing thelong-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin. Ther. 27: 1912-1921 (2005). *

• Goldberg Green M, Bragg J, Rosenman KS, Keltz Pomeranz M. Pustular psoriasis of pregnancy in a patient whose dermatosis showed features of acute generalized exanthematous pustulosis. Int. J. Dermatol. 48: 299-303 (2009).

• Goldstein ES, Rubin PH. Endoscopic therapy for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 237-243 (2003).

• Golovnova EV, Il'chenko LIu, Tsaregorodtseva TM, Serova TI, Gudkova RV, Shepeleva SD, Tkachev VD. Primary biliary cirrhosis: 12-year experience in observation. Ter. Arkh. 75: 26-30 (2003).

• Gomez RL, Griffin JW Jr, Squires JE. Prolonged relief of intractable pruritus in primary sclerosing cholangitis by plasmapheresis. J. Clin. Gastroenterol. 8: 301-303 (1986).

• Gong Y, Christensen E, Gluud C. Cyclosporin A for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD005526 (2007). *

• Gong Y, Christensen E, Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD006000 (2007). *

• Gong Y, Frederiksen S, Gluud C. D-penicillamine for primary biliary cirrhosis. Cochrane Database Syst. Rev. 4: CD004789 (2004). *

• Gong Y, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD004385 (2005). *

• Gong Y, Gluud C. Colchicine for primary biliary cirrhosis: a Cochrane hepato-biliary group systematic review of randomized clinical trials. Am. J. Gastroenterol. 100: 1-10 (2005). *

• Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst. Rev. 2: CD004481 (2004). *

• Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am. J. Gastroenterol. 102: 1799-1807 (2007). *

• Gong Y, Huang ZB, Christensen E, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD000551 (2008). *

• Gong Y, Klingenberg SL, Gluud C. Systematic review and meta-analysis: D-penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis - Cochrane Hepato-Biliary Group. Aliment. Pharmacol. Ther. 24: 1535-1544 (2006). *

• Gonul M, Gul U, Cakmak SK, Kilic S. Unconventional medicine in dermatology outpatients in Turkey. Int. J. Dermatol. 48: 639-644 (2009).

• Gonzalez M, Ribalta J, Reyes H, Klinger J, Maggiolo P, Varleta P, Hernandez I, Delgado M, Donoso S. Primary biliary cirrhosis. The clinical experience in 31 patients. Rev. Med. Chil. 118: 1350-1354 (1990).

• Gopal DV, Corless CL, Rabkin JM, Olyaei AJ, Rosen HR. Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantation. J. Clin. Gastroenterol. 37: 344-347 (2003).

• Gordon F. Recurrent primary sclerosing cholangitis: clinical diagnosis and long-term management issues. Liver Transpl. 12: S73-S75 (2006). *

• Gowda S, Goldblum OM, McCall WV, Feldman SR. Factors affecting sleep quality in patients with psoriasis. J. Am. Acad. Dermatol. Nov 25 [Epub ahead of print] (2009).

• Goyal NN, Wong GA. Psoriasis or crusted scabies. Clin. Exp. Dermatol. 33: 211-212 (2008). *

• Greaves MW. Antihistamines in dermatology. Skin Pharmacol. Physiol. 18: 220-229 (2005).

• Greaves MW. Recent advances in pathophysiology and current management of itch. Ann. Acad. Med. Singapore 36: 788-785 (2007). *

• Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch. Dis. Child. 69: 141-143 (1993).

• Greisenegger EK, Zimprich A, Zimprich F, Stingl G, Kopp T. Analysis of the prodynorphin promoter polymorphism in atopic dermatitis and disease-related pruritus. Clin. Exp. Dermatol. 34: 728-730 (2009). *

• Griffiths W, Davies S, Gibbs P, Thillainayagam A, Alexander G. Liver transplantation in an adult with sclerosing cholangitis due to Langerhans cell histiocytosis. J. Hepatol. 44: 829-831 (2006). *

• Grimaud JC, Bourliere M. Contraception and hepatogastroenterology. Fertil. Contracept. Sex 17: 407-413 (1989).

• Grune S, Mullhaupt B, Moradpour D, Munch R, Siegenthaler-Zuber G, Siegenthaler W. Primary sclerosing cholangitis. Dtsch. Med. Wochenschr. 116: 1095-1100 (1991).

• Gu EL, Yao GB. The clinical characteristics of primary biliary cirrhosis in China: a systimatic review. Zhonghua Gan Zang Bing Za Zhi 17: 861-866 (2009).

• Gunsar F, Akarca US, Ersoz G, Karasu Z, Yuce G, Batur Y. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Hepatogastroenterology 49: 1195-1200 (2002).

• Gupta RC, Seibold JR, Krishnan MR, Steigerwald JC. Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis. Clin. Exp. Immunol. 58: 68-76 (1984). *

• Halabi-Tawil M, Ruemmele FM, Fraitag S, Rieux-Laucat F, Neven B, Brousse N, De Prost Y, Fischer A, Goulet O, Bodemer C. Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Br. J. Dermatol. 160: 645-651 (2009). *

• Han L, Somani AK, Huang Q, Fang X, Jin Y, Xiang LH, Zheng ZZ. Evaluation of 308-nm monochromatic excimer light in the treatment of psoriasis vulgaris and palmoplantar psoriasis. Photodermatol. Photoimmunol. Photomed. 24: 231-236 (2008).

• Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 64: 1767-1777 (2004).

• Hardikar W, Kansal S, Oude Elferink RP, Angus P. Intrahepatic cholestasis of pregnancy: when should you look further? World J. Gastroenterol. 15: 1126-1129 (2009). *

• Hasan MK, Tierney WM, Baker MZ. Severe cholestatic jaundice in hyperthyroidism after treatment with 131-iodine. Am. J. Med. Sci. 328: 348-350 (2004).

• Hasanein P. Two histamine H2 receptor antagonists, zolantidine and cimetidine, modulate nociception in cholestatic rats. J. Psychopharmacol. Oct 13 [Epub ahead of print] (2009).

• Hawro T, Miniszewska J, Chodkiewicz J, Sysa-Jedrzejowska A, Zalewska A. Anxiety, depression and social support in patients with psoriasis. Przegl. Lek. 64: 568-571 (2007).

• Hay JE. Liver disease in pregnancy. Hepatology 47: 1067-1076 (2008). *

• Hay JE. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection? Liver Transpl. Surg. 4: S9-S17 (1998).

• Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 31: 1005-1013 (2000). *

• Heathcote EJ. Is rifampin a safe and effective treatment for pruritus caused by chronic cholestasis? Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 200-201 (2007). *

• Heathcote EJ. Diagnosis and management of cholestatic liver disease. Clin. Gastroenterol. Hepatol. 5: 776-782 (2007). *

• Heathcote J. Diagnosis of primary biliary liver diseases, overlap syndromes and changing diagnosis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 55 (2004). *

• Heathcote J. Update on primary biliary cirrhosis. Can. J. Gastroenterol. 14: 43-48 (2000). *

• Heathcote J. Treatment of primary biliary cirrhosis. J. Gastroenterol. Hepatol. 11: 605-609 (1996).

• Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 70: 656-660 (1976).

• Heinrich I, Nashitz J, Yeshurun D. Combined cholestatic jaundice due to cholelithiasis and primary biliary cirrhosis. Harefuah. 123: 392-394, 435 (1992).

• Hendrickse MT, Rigney E, Giaffer MH, Soomro I, Triger DR, Underwood JC, Gleeson D. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 117: 400-407 (1999). *

• Hengge UR, Krause W, Hofmann H, Stadler R, Gross G, Meurer M, Brinkmeier T, Frosch P, Moll I, Fritsch P, Muller K, Meykadeh N, Marini A, Ruzicka T, Gollnick H. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br. J. Dermatol. 155: 1021-1028 (2006). *

• Hernando-Harder AC, Booken N, Goerdt S, Singer MV, Harder H. Helicobacter pylori infection and dermatologic diseases. Eur. J. Dermatol. 19: 431-444 (2009).

• Hess J, Thorens J, Pache I, Troillet FX, Moradpour D, Gonvers JJ. Auto-immune liver diseases and their treatment. Rev. Med. Suisse. 1: 242, 245-247 (2005).

• Heurgue A, Vitry F, Diebold MD, Yaziji N, Bernard-Chabert B, Pennaforte JL, Picot R, Louvet H, Fremond L, Geoffroy P, Schmit JL, Cadiot G, Thiefin G. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol. Clin. Biol. 31: 17-25 (2007). *

• Hoek FJ, Grijm R, Sanders GT, Tytgat GN, Wilmink JM. Removal of bile acids from the blood by hemodialysis with a polyacrylonitril membrane: treatment of pruritus of cholestatic disease. Digestion 23: 135-140 (1982).

• Hoensch HP, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus EE. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur. J. Clin. Pharmacol. 28: 475-477 (1985).

• Hofmann AF. Cholestatic liver disease: pathophysiology and therapeutic options. Liver 22 Suppl. 2: 14-19 (2002).

• Hofmann AF. Rifampicin and treatment of cholestatic pruritus. Gut 51: 756-757 (2002). *

• Hofmann AF, Huet PM. Nasobiliary drainage for cholestatic pruritus. Hepatology 43: 1170-1171 (2006). *

• Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin. Immunopathol. 31: 283-307 (2009). *

• Holtmeier J, Leuschner U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Digestion 64: 137-150 (2001). *

• Hong-Curtis J, Yeh MM, Jain D, Lee JH. Rapid progression of autoimmune hepatitis in the background of primary sclerosing cholangitis. J. Clin. Gastroenterol. 38: 906-909 (2004).

• Honma Y, Arai I, Futaki N, Hashimoto Y, Sugimoto M, Sakurai T, Nakaike S. Cyclooxygenase-1 inhibition delays recovery of the cutaneous barrier disruption caused by mechanical scratching in mice. Br. J. Dermatol. 156: 1178-1187 (2007). *

• Horsmans Y, Geubel AP. Pruritus associated with cholestatic liver disease. Ann. Intern. Med. 125: 701 (1996). *

• Huang CS, Lichtenstein DR. Treatment of biliary problems in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 8: 117-126 (2005).

• Huang JF, Thurmond RL. The new biology of histamine receptors. Curr. Allergy Asthma Rep. 8: 21-27 (2008).

• Huang WM, Seubert DE, Donnelly JG, Liu M, Javitt NB. Intrahepatic cholestasis of pregnancy: detection with urinary bile acid assays. J. Perinat. Med. 35: 486-491 (2007).

• Hug B, Fried R, Terracciano L. Pruritus in liver disease: case report with discussion. Schweiz. Rundsch. Med. Prax. 87: 1805-1810 (1998).

• Hull K, Horenstein R, Naglieri R, Munir K, Ghany M, Celi FS. Two cases of thyroid storm-associated cholestatic jaundice. Endocr. Pract. 13: 476-480 (2007).

• Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 107: 1844-1847 (1994).

• Huster D, Schubert C, Achenbach H, Caca K, Mossner J, Berr F. Successful clinical application of extracorporal albumin dialysis in a patient with benign recurrent intrahepatic cholestasis (BRIC). Z. Gastroenterol. 39 (Suppl. 2): 13-14 (2001).

• Hwang SJ, Chan CY, Lee SD, Wu JC, Tsay SH, Lo KJ. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. J. Gastroenterol. Hepatol. 8: 217-223 (1993).

• Ichikawa T, Sato H, Kaira K, Oh-I S, Kakizaki S, Sato K, Takagi H, Mori M. Prolonged intrahepatic cholestasis after exposure to loxoprofen. Clin. Ther. 30: 2402-2406 (2008).

• Inan S, Cowan A. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol. Biochem. Behav. 85: 39-43 (2006). *

• Inan S, Cowan A. Reduced kappa-opioid activity in a rat model of cholestasis. Eur. J. Pharmacol. 518: 182-186 (2005). *

• Inoue K, Hirohara J, Nakano T, Seki T, Sasaki H, Higuchi K, Ohta Y, Onji M, Muto Y, Moriwaki H. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 15: 70-77 (1995).

• Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br. J. Dermatol. 147: 523-527 (2002). *

• Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin. Liver Dis. 27: 214-226 (2007). *

• Ismail H, Kalicinski P, Markiewicz M, Jankowska I, Pawlowska J, Kluge P, Eliadou E, Kaminski A, Szymczak M, Drewniak T, Revillon Y. Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. Pediatr. Transplant. 3: 219-224 (1999).

• Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T, Maeda T, Onishi S. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol. Res. 16: 12-18 (1999).

• Jacquemin E. Progressive familial intrahepatic cholestasis and hereditary anomalies of hepatocellular metabolism of bile acids. Arch. Pediatr. 5: 45-53 (1998).

• Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, Sokal EM, Bernard O. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25: 519-523 (1997). *

• Jacquemin E, Setchell KD, O'Connell NC, Estrada A, Maggiore G, Schmitz J, Hadchouel M, Bernard O. A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J. Pediatr. 125: 379-384 (1994).

• James IG, Loria-Kanza Y, Jones TC. Short-duration topical treatment of tinea pedis using terbinafine emulsion gel: results of a dose-ranging clinical trial. J. Dermatolog. Treat. 18: 163-168 (2007).

• Janczewska I, Olsson R, Hultcrantz R, Broome U. Pregnancy in patients with primary sclerosing cholangitis. Liver 16: 326-330 (1996).

• Jansen PL, van der Lelie H. Intrahepatic cholestasis and biliary cirrhosis associated with extrahepatic Hodgkin's disease. Neth. J. Med. 44: 99-102 (1994).

• Jaroszewicz J, Pelszynska MJ, Kalinowska A, Wierzbicka I, Flisiak R, Prokopowicz D. Analysis of prognostic factors in patients with autoimmune hepatitis. Pol. Arch. Med. Wewn. 115: 329-335 (2006).

• Javitt NB. Cholestatic liver disease and its management. Baillieres Clin. Gastroenterol. 3: 423-430 (1989).

• Javouhey E, Ranchin B, Lachaux A, Boillot O, Martin X, Floret D, Cochat P. Long-lasting extracorporeal albumin dialysis in a child with end-stage renal disease and severe cholestasis. Pediatr. Transplant. 13: 235-239 (2009). *

• Jazia EB, Khalifa M, Abdelkader AB, Kaabia N, Ghannouchi N, Braham A, Letaief A, Bahri F. A case of primary biliary cirrhosis associated with pernicious anemia: a case report. Cases J. 3: 11 (2010). *

• Jiang J, He M. Clinical features of primary biliary cirrhosis and treatment of it by integrated traditional Chinese and western medicine. Zhong Xi Yi Jie He Xue Bao 1: 99-102 (2003).

• Johnson H, Bossenbroek NM, Rosenman K, Meehan SA, Robles M, Pomeranz MK. Chronic cutaneous lupus erythematosus in vitiligo. Dermatol. Online J. 14: 10 (2008).

• Jones DE. Addison's other disease: primary biliary cirrhosis as a model autoimmune disease. Clin. Med. 3: 351-356 (2003). *

• Jones EA. Trials of opiate antagonists for the pruritus of cholestasis: primary efficacy endpoints and opioid withdrawal-like reactions. J. Hepatol. 37: 863-865 (2002). *

• Jones EA, Bergasa NV. The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur. J. Gastroenterol. Hepatol. 11: 623-631 (1999).

• Jones EA, Bergasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can. J. Gastroenterol. 14: 33-40 (2000). *

• Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 29: 1003-1006 (1999). *

• Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 118: 431-432 (2000). *

• Jones EA, Molenaar HA, Oosting J. Ondansetron and pruritus in chronic liver disease: a controlled study. Hepatogastroenterology 54: 1196-1199 (2007).

• Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 95: 547-552 (2002). *

• Jones EA, Zylicz Z. Treatment of pruritus caused by cholestasis with opioid antagonists. J. Palliat. Med. 8: 1290-1294 (2005).

• Jorge A, Fay O, Palazzi J, Sanchez D, Tanno H, Diaz M. Determination of cholic and sulfolithocholic acids in various hepatopathies. Acta Gastroenterol. Latinoam. 12: 143-147 (1982).

• Joshi GG, Thakur BS, Sircar S, Namdeo A, Jain AK. Role of intravenous naloxone in severe pruritus of acute cholestasis. Indian J. Gastroenterol. 28: 180-182 (2009). *

• Kaaja RJ, Kontula KK, Raiha A, Laatikainen T. Treatment of cholestasis of pregnancy with peroral activated charcoal. A preliminary study. Scand. J. Gastroenterol. 29: 178-181 (1994).

• Kagalwalla AF, Al Amir AR, Khalifa A, Sylven M, Al Ajaji S, Kagalwalla YA. Progressive familial intrahepatic cholestasis (Byler's disease) in Arab children. Ann. Trop. Paediatr. 15: 321-327 (1995).

• Kamath BM, Schwarz KB, Hadzic N. Alagille syndrome and liver transplantation. J. Pediatr. Gastroenterol. Nutr. 50: 11-15 (2010).

• Kamimura T, Yoshida T, Ito S, Tashiro T. Primary biliary cirrhosis: symptoms, laboratory data and diagnosis. Nippon Rinsho 52: 246-250 (1994).

• Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J. Gastroenterol. 38: 573-578 (2003). *

• Kao JH, Lai MY, Lin JT, Yang PM, Sheu JC, Chen DS, Sung JL, Wang TH. Therapeutic effect of ursodeoxycholic acid on early-stage primary biliary cirrhosis. J. Formos. Med. Assoc. 90: 970-974 (1991).

• Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 101: 1332-1338 (1991).

• Kaplan MM, Schmid C, Provenzale D, Sharma A, Dickstein G, McKusick A. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 117: 1173-1180 (1999). *

• Kardorff R, Melter M, Rodeck B, Brodehl J. Long-term ursodeoxycholic acid treatment of cholestatic liver diseases in childhood - clinical and biochemical effects. Klin. Padiatr. 208: 118-122 (1996).

• Kaw M, Silverman WB, Rabinovitz M, Schade RR. Biliary tract calculi in primary sclerosing cholangitis. Am. J. Gastroenterol. 90: 72-75 (1995).

• Keitel V, Vogt C, Haussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 131: 624-629 (2006). *

• Keithi-Reddy SR, Patel TV, Armstrong AW, Singh AK. Uremic pruritus. Kidney Int. 72: 373-377 (2007). *

• Kenngott S, Lohse P, Beuers U. Intrahepatic cholestasis in pregnancy. What to consider in jaundice and pruritus. MMW Fortschr. Med. 144: 41-44 (2002).

• Khalaf AT, Li W, Jinquan T. Current advances in the management of urticaria. Arch. Immunol. Ther. Exp. (Warsz.) 56: 103-114 (2008).

• Khaled A, Sellami A, Fazaa B, Kharfi M, Zeglaoui F, Kamoun MR. Acquired erythroderma in adults: a clinical and prognostic study. J. Eur. Acad. Dermatol. Venereol. Dec 17 [Epub ahead of print] (2009).

• Khandelwal M, Malet PF. Pruritus associated with cholestasis. A review of pathogenesis and management. Dig. Dis. Sci. 39: 1-8 (1994).

• Khanlou H, Sass D, Rothstein K, Manzarbeitia C, Reich D, Jacobson L, Fleischer D, Munoz SJ. Idiopathic adulthood ductopenia: case report and review of the literature. Arch. Intern. Med. 160: 1033-1036 (2000). *

• Khopkar U, Pande S. Etiopathogenesis of pruritus due to systemic causes: implications for treatment. Indian J. Dermatol. Venereol. Leprol. 73: 215-217 (2007). *

• Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 26: 943-948 (2006). *

• Kim JH, Kim BH, Kim YW, Park JC, Jung YH, Lee BO, Han YS, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R. Autoimmune cholangitis in a patient with thymoma. J. Gastroenterol. Hepatol. 19: 1324-1327 (2004). *

• Kippes W, Schmidt E, Roth A, Rzany B, Brocker EB, Zillikens D. Immunopathologic changes in 115 patients with bullous pemphigoid. Hautarzt. 50: 866-872 (1999).

• Kirby CP, Freeman JK, Ford WD, Davidson GP, Furness ME. Malrotation with recurrent volvulus presenting with cholestasis, pruritus, and pancreatitis. Pediatr. Surg. Int. 16: 130-131 (2000).

• Kirby DF, Blei AT, Rosen ST, Vogelzang RL, Neiman HL. Primary sclerosing cholangitis in the presence of a lupus anticoagulant. Am. J. Med. 81: 1077-1080 (1986).

• Kircik L. The evolving role of therapeutic shampoos for targeting symptoms of inflammatory scalp disorders. J. Drugs Dermatol. 9: 41-48 (2010).

• Kircik L. Efficacy and safety of topical calcitriol 3 microg/g ointment, a new topical therapy for chronic plaque psoriasis. J. Drugs Dermatol. 8: s9-s16 (2009).

• Kircik LH. Tretinoin microsphere gel pump 0.04% versus tazarotene cream 0.05% in the treatment of mild-to-moderate facial acne vulgaris. J. Drugs Dermatol. 8: 650-654 (2009).

• Kligman AM, Greaves MW, Steinman H. Water-induced itching without cutaneous signs. Aquagenic pruritus. Arch. Dermatol. 122: 183-186 (1986).

• Klomp LW, Bull LN, Knisely AS, van Der Doelen MA, Juijn JA, Berger R, Forget S, Nielsen IM, Eiberg H, Houwen RH. A missense mutation in FIC1 is associated with Greenland familial cholestasis. Hepatology 32: 1337-1341 (2000). *

• Kloppel G, Kirchhof M, Berg PA. Natural course of primary biliary cirrhosis. I. A morphological, clinical and serological analysis of 103 cases. Liver 2: 141-151 (1982).

• Kluger N, Raison-Peyron N, Rigole H, Bessis D, Blanc F, Guillot B. Generalized pruritus revealing hereditary haemochromatosis. Acta Derm. Venereol. 87: 277 (2007).

• Kneppelhout JC, Mulder CJ, van Berge Henegouwen GP, de Vries RA, Brandt KH. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease. Neth. J. Med. 41: 11-16 (1992).

• Ko MC, Lee H, Song MS, Sobczyk-Kojiro K, Mosberg HI, Kishioka S, Woods JH, Naughton NN. Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J. Pharmacol. Exp. Ther. 305: 173-179 (2003). *

• Kocak N, Gurakan F, Yuce A, Caglar M, Kale G, Gogus S. Nonsyndromic paucity of interlobular bile ducts: clinical and laboratory findings of 10 cases. J. Pediatr. Gastroenterol. Nutr. 24: 44-48 (1997). *

• Kolodny L, Horstman LL, Sevin BU, Brown H, Ahn YS. Danazol relieves refractory pruritus associated with myeloproliferative disorders and other diseases. Am. J. Hematol. 51: 112-116 (1996).

• Kolyvanos Naumann U, Kaser L, Vetter W. Primary biliary cirrhosis. Chief symptoms: fatigue, pruritus, occasionally hepatomegaly. Schweiz. Rundsch. Med. Prax. 93: 87-93 (2004).

• Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129: 894-901 (2005). *

• Kondrackiene J, Beuers U, Zalinkevicius R, Tauschel HD, Gintautas V, Kupcinskas L. Predictors of premature delivery in patients with intrahepatic cholestasis of pregnancy. World J. Gastroenterol. 13: 6226-6230 (2007). *

• Koshy A, Ramesh H, Mahadevan P, Mukkada RJ, Francis VJ, Chettupuzha AP, Mathew PG, Cyriac J, Augustine P. Progressive familial intrahepatic cholestasis: a case with improvement in liver tests and growth following partial external biliary diversion. Indian J. Gastroenterol. 28: 107-108 (2009). *

• Koskinas J, Raptis I, Manika Z, Hadziyannis S. Overlapping syndrome of autoimmune hepatitis and primary sclerosing cholangitis associated with pyoderma gangrenosum and ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 11: 1421-1424 (1999).

• Koulentaki M, Ioannidou D, Stefanidou M, Maraki S, Drigiannakis I, Dimoulios P, Melono JM, Tosca A, Kouroumalis EA. Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am. J. Gastroenterol. 101: 541-546 (2006). *

• Kranke B, Trummer M, Brabek E, Komericki P, Turek TD, Aberer W. Etiologic and causative factors in perianal dermatitis: results of a prospective study in 126 patients. Wien. Klin. Wochenschr. 118: 90-94 (2006).

• Kraus MR, Scheurlen M. Diagnosis and treatment of intrahepatic cholestasis syndrome. MMW Fortschr. Med. 146: 34-37 (2004).

• Kremer AE, Beuers U, Oude Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs 68: 2163-2182 (2008).

• Kubitz R, Keitel V, Burdelski M, Haussinger D. Regulation of hepatobiliary transporters in chronic cholestasis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 33-35 (2006). *

• Kuga K, Nishifuji K, Iwasaki T. Cyclosporine A inhibits transcription of cytokine genes and decreases the frequencies of IL-2 producing cells in feline mononuclear cells. J. Vet. Med. Sci. 70: 1011-1016 (2008). *

• Kuiper EM, den Ouden-Muller JW, van Buuren HR. Primary biliary cirrhosis. Ned. Tijdschr. Geneeskd. 153: A483 (2009).

• Kumagi T, Heathcote JE. Primary biliary cirrhosis. Orphanet J. Rare Dis. 3: 1 (2008). *

• Kurbegov AC, Setchell KD, Haas JE, Mierau GW, Narkewicz M, Bancroft JD, Karrer F, Sokol RJ. Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile. Gastroenterology 125: 1227-1234 (2003). *

• Kurihara T, Akimoto M, Abe K, Ishiguro H, Niimi A, Maeda A, Shigemoto M, Yamashita K, Yokoyama I, Suzuki Y, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin. Ther. 15: 890-898 (1993).

• Kurtovic J, Riordan S. Clinical aspects of primary biliary cirrhosis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 31-32. October 15-16 (2003). *

• La Shell MS, Tankersley MS, Guerra A. Pruritus, papules, and perspiration. Ann. Allergy Asthma Immunol. 98: 299-302 (2007).

• Laifer SA, Stiller RJ, Siddiqui DS, Dunston-Boone G, Whetham JC. Ursodeoxycholic acid for the treatment of intrahepatic cholestasis of pregnancy. J. Matern. Fetal. Med. 10: 131-135 (2001).

• Lammert F, Marschall HU, Matern S. Intrahepatic cholestasis of pregnancy. Curr. Treat. Options Gastroenterol. 6: 123-132 (2003).

• Lane TK, Kamino H, Walters RF, Meehan S, Pomeranz MK. Lichen planopilaris and psoriasis. Dermatol. Online J. 14: 4 (2008).

• Langner MD, Maibach HI. Pruritus measurement and treatment. Clin. Exp. Dermatol. 34: 285-288 (2009). *

• Lasker JN, Sogolow ED, Sharim RR. The role of an online community for people with a rare disease: content analysis of messages posted on a primary biliary cirrhosis mailinglist. J. Med. Internet Res. 7: e10 (2005). *

• Lauterburg BH, Pineda AA, Dickson ER, Baldus WP, Taswell HF. Plasmaperfusion for the treatment of intractable pruritus of cholestasis. Mayo Clin. Proc. 53: 403-407 (1978).

• Lauterburg BH, Taswell HF, Pineda AA, Dickson ER, Burgstaler EA, Carlson GL. Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads. Lancet 2: 53-55 (1980).

• Lazaridis KN, Lindor KD. Primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 2: 473-480 (1999).

• Lebrec D, Sicot C, Degott C, Benhamou JP. Portal hypertension and primary biliary cirrhosis. Digestion 14: 220-226 (1976).

• Lee B, Trung Trinh H, Bae EA, Jung K, Kim DH. Mangiferin inhibits passive cutaneous anaphylaxis reaction and pruritus in mice. Planta Med. 75: 1415-1417 (2009).

• Lee RH, Goodwin TM, Greenspoon J, Incerpi M. The prevalence of intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles population. J. Perinatol. 26: 527-532 (2006).

• Lee RH, Incerpi MH, Miller DA, Pathak B, Goodwin TM. Sudden fetal death in intrahepatic cholestasis of pregnancy. Obstet. Gynecol. 113: 528-531 (2009).

• Lee WS, Saw CB, Sarji SA. Autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome in a child: diagnostic usefulness of magnetic resonance cholangiopancreatography. J. Paediatr. Child. Health 41: 225-227 (2005).

• Leevy CB, Holt J Jr, Buniak B. Immunologic effects of ursodeoxycholic acid in primary biliary cirrhosis. J. Assoc. Acad. Minor Phys. 4: 30-32 (1993).

• Leevy CB, Koneru B, Klein KM. Recurrent familial prolonged intrahepatic cholestasis of pregnancy associated with chronic liver disease. Gastroenterology 113: 966-972 (1997). *

• Lemoine M, Revaux A, Francoz C, Ducarme G, Brechignac S, Jacquemin E, Uzan M, Ganne-Carrie N. Albumin liver dialysis as pregnancy-saving procedure in cholestatic liver disease and intractable pruritus. World J. Gastroenterol. 14: 6572-6574 (2008). *

• Lengyel G, Feher J. Intrahepatic cholestasis of pregnancy. Orv. Hetil. 145: 2103-2105 (2004).

• Lengyel G, Feher R, Gardo S, Feher J. Ursodeoxycholic acid treatment in intrahepatic cholestasis of pregnancy. A case report. Orv. Hetil. 143: 2885-2888 (2002).

• Lesma E, Grande V, Di Giulio AM, Castellana P, Crosignani A, Cerri A, Gorio A. G protein-mediated signal transduction is affected in primary biliary cirrhosis. Hepatol. Res. 35: 45-52 (2006).

• Leuschner U. Primary biliary cirrhosis - presentation and diagnosis. Clin. Liver Dis. 7: 741-758 (2003).

• Leuschner U. Cholestatic hepatopathy: primary biliary cirrhosis. Schweiz. Rundsch. Med. Prax. 89: 1043-1048 (2000).

• Leuschner U. Ursodeoxycholic acid therapy in primary biliary cirrhosis. Scand. J. Gastroenterol. Suppl. 204: 40-46 (1994).

• Leuschner U, Manns MP, Eisebitt R. Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis. Z. Gastroenterol. 43: 1051-1059 (2005).

• Levy C, Lindor KD. Management of primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 6: 493-498 (2003).

• Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 38: S24-S37 (2003). *

• Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).

• Levy C, Lindor KD. Drug-induced cholestasis. Clin. Liver Dis. 7: 311-330 (2003).

• LeWitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 68: 1262-1267 (2007).

• Lieberman DA, Keeffe EB, Stenzel P. Severe and prolonged oral contraceptive jaundice. J. Clin. Gastroenterol. 6: 145-148 (1984).

• Lillemoe KD, Pitt HA, Cameron JL. Sclerosing cholangitis. Adv. Surg. 21: 65-92 (1988).

• Lillemoe KD, Pitt HA, Cameron JL. Primary sclerosing cholangitis. Surg. Clin. North Am. 70: 1381-1402 (1990).

• Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N. Engl. J. Med. 336: 691-695 (1997). *

• Lindor KD. Primary biliary cirrhosis: questions and promises. Ann. Intern. Med. 126: 733-735 (1997). *

• Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106: 1284-1290 (1994).

• Ling SC. Congenital cholestatic syndromes: what happens when children grow up? Can. J. Gastroenterol. 21: 743-751 (2007). *

• Lipozencic J. Thematic Issue of Acta Dermatovenerologica Croatica - Psoriasis - State-of-the-Art. Acta Dermatovenerol. Croat. 17: 161 (2009).

• Listrom C, Holt K. Inflammatory bowel disease. Emerg. Med. 36: 24-28 (2004).

• Lo TK, Lau WL, Lam HS, Leung WC, Chin RKh. Obstetric cholestasis in Hong Kong-local experience with eight consecutive cases. Hong Kong Med. J. 13: 387-391 (2007).

• Lockard O Jr, Harmon C, Nolph K, Irvin W. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Ann. Intern. Med. 85: 333-335 (1976).

• Logan RF, Ferguson A, Finlayson ND, Weir DG. Primary biliary cirrhosis and coeliac disease: an association? Lancet 1: 230-233 (1978).

• Longo M, Crosignani A, Podda M. Hyperlipidemia in chronic cholestatic liver disease. Curr. Treat. Options Gastroenterol. 4: 111-114 (2001).

• Lonsdale-Eccles AA, Carmichael AJ. Opioid antagonist for pruritus of cholestasis unmasking bony metastases. Acta Derm. Venereol. 89: 90 (2009).

• Lorente S, Montoro MA. Cholestasis of pregnancy. Gastroenterol. Hepatol. 30: 541-548 (2007).

• Lovell P Rn-1, Vender RB Md-2. Management and treatment of pruritus. Skin Therapy Lett. 12: 1-6 (2007).

• Lozano A, Vildosola H, Takano J, Vargas G, Uribe R, Moreno C. Clinical and immunological profile in 22 patients with primary biliary cirrhosis. Rev. Gastroenterol. Peru. 20: 14-24 (2000).

• Lu W, Sun G. Clinical characteristics of primary biliary cirrhosis with Sjogren's syndrome of 20 cases. Zhonghua Nei Ke Za Zhi 40: 747-749 (2001).

• Lucey MR, Neuberger JM, Williams R. Primary biliary cirrhosis in men. Gut 27: 1373-1376 (1986). *

• Lugon JR. Uremic pruritus: a review. Hemodial. Int. 9: 180-188 (2005).

• Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin. Liver Dis. 8: 133-149 (2004).

• Luketic VA, Shiffman ML. Benign recurrent intrahepatic cholestasis. Clin. Liver Dis. 3: 509-528, viii (1999).

• Lykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut 49: 431-435 (2001). *

• Madej A, Reich A, Orda A, Szepietowski JC. Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. J. Eur. Acad. Dermatol. Venereol. 21: 72-78 (2007). *

• Maekawa T, Yamaguchi-Miyamoto T, Nojima H, Kuraishi Y. Effects of naltrexone on spontaneous itch-associated responses in NC mice with chronic dermatitis. Jpn. J. Pharmacol. 90: 193-196 (2002). *

• Maffei M, Hadengue A. Cholestasis of adult. 2. Clinical signs and symptomatic treatment. Rev. Med. Suisse. 2: 1965-1966, 1969-1971 (2006).

• Mahajan S, Koranne RV, Sharma SK. Cutaneous manifestation of diabetes melitus. Indian J. Dermatol. Venereol. Leprol. 69: 105-108 (2003).

• Mahe E, Lacaille F, Hadj-Rabia S, Bodemer C, De Prost Y, Hamel-Teillac D. Hereditary cholestasis, an unusual etiology of pruritus in the infant. Ann. Dermatol. Venereol. 131: 1092-1094 (2004).

• Maintz L, Novak N. Histamine and histamine intolerance. Am. J. Clin. Nutr. 85: 1185-1196 (2007). *

• Majeed M, Babu A. Cholestasis secondary to hyperthyroidism made worse by methimazole. Am. J. Med. Sci. 332: 51-53 (2006).

• Majeski CJ, Johnson JA, Davison SN. Itch severity scale: a self-report instrument for the measurement of pruritus severity. Br. J. Dermatol. 156: 667-673 (2007).

• Mallat A, Zafrani ES, Metreau JM, Dhumeaux D. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig. Dis. Sci. 42: 1486-1488 (1997). *

• Malomuzh OI, Krel' PE, Got'e SV, Tsirul'nikova OM. Prognosis for patients with chronic diseases of the liver in formulating indications to orthotopic liver transplantation. Ter. Arkh. 81: 45-50 (2009).

• Marangoni R. Molecular adsorption in liver failure. G. Ital. Nefrol. 22 Suppl. 31: S156-S160 (2005).

• Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, Loguercio C, Apolone G, Niero M, Abbiati R; Italian Study Group for quality of life in cirrhosis. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 120: 170-178 (2001). *

• Marecek Z. Therapy of chronic cholestasis. Vnitr. Lek. 41: 193-195 (1995).

• Marinaccio M, Pinto V, Sambati GS, Papandrea D, De Veteris M. Uncomplicated pregnancy in patients with unrecognized primary biliary cirrhosis. Minerva Ginecol. 44: 273-276 (1992).

• Marotta PJ, LaRusso NF, Wiesner RH. Sclerosing cholangitis. Baillieres Clin. Gastroenterol. 11: 781-800 (1997).

• Marpeau L, Benifla JL, Chazouilleres O, Larue L, Pigne A, Poupon R, Barrat J. Primary biliary cirrhosis and pregnancy. Apropos of a clinical case. Review of the literature. J. Gynecol. Obstet. Biol. Reprod. (Paris) 20: 805-807 (1991).

• Maruani A, Labarthe F, Dupre T, Le Bidre E, Georgesco G, Lorette G. Hypercarotenaemia in an infant. Ann. Dermatol. Venereol. 137: 32-35 (2010).

• Matsuzaki Y, Doy M, Tanaka N, Shoda J, Osuga T, Nakano M, Aikawa T. Biochemical and histological changes after more than four years of treatment of ursodeoxycholic acid in primary biliary cirrhosis. J. Clin. Gastroenterol. 18: 36-41 (1994).

• Matsuzaki Y, Tanaka N, Osuga T, Aikawa T, Shoda J, Doi M, Nakano M. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am. J. Gastroenterol. 85: 15-23 (1990).

• Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 45: 666-674 (2007). *

• Mays JK. The active management of intrahepatic cholestasis of pregnancy. Curr. Opin. Obstet. Gynecol. Jan 29 [Epub ahead of print] (2010).

• McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf. 25: 913-927 (2002).

• McCormick PA, Scott F, Epstein O, Burroughs AK, Scheuer PJ, McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J. Hepatol. 21: 496-499 (1994).

• McDonald JA. Cholestasis of pregnancy. J. Gastroenterol. Hepatol. 14: 515-518 (1999). *

• McLoughlin M, Enns R. Endoscopy in the management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 10: 177-185 (2008).

• Mease PJ, Hobbs K, Chalmers A, El-Gabalawy H, Bookman A, Keystone E, Furst DE, Anklesaria P, Heald AE. Local delivery of a recombinant adeno-associated vector containing a tumor necrosis factor-alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Ann. Rheum. Dis. 68: 1247-1254 (2009).

• Mela M, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment. Pharmacol. Ther. 17: 857-870 (2003). *

• Melter M, Rodeck B, Kardorff R, Hoyer PF, Petersen C, Ballauff A, Brodehl J. Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am. J. Gastroenterol. 95: 3522-3528 (2000). *

• Menter A. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial. Cutis 80: S12-S19 (2007).

• Mentha G, Huber O, Le Coultre C, Widmann JJ, Meyer P, Klopfenstein C, Morel P, Suter P, Rohner A. Liver transplantation for primary biliary cirrhosis. Schweiz. Med. Wochenschr. 122: 648-651 (1992).

• Mercadante S, Villari P, Fulfaro F. Rifampicin in opioid-induced itching. Support Care Cancer 9: 467-468 (2001). *

• Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J. Am. Acad. Dermatol. 41: 533-539 (1999).

• Michaels A, Levy C. Endoscopic and surgical management of primary sclerosing cholangitis. Medscape J. Med. 10: 242 (2008). *

• Michaels A, Levy C. The medical management of primary sclerosing cholangitis. Medscape J. Med. 10: 61 (2008). *

• Milkiewicz P, Gallagher R, Chambers J, Eggington E, Weaver J, Elias E. Obstetric cholestasis with elevated gamma glutamyl transpeptidase: incidence, presentation and treatment. J. Gastroenterol. Hepatol. 18: 1283-1286 (2003). *

• Miros M, Kerlin P, Walker N, Harper J, Lynch S, Strong R. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis before transplantation. Gut 32: 1369-1373 (1991). *

• Mirza R, Abbas Z, Luck NH, Azam SM, Aziz S, Hassan SM, Soomro GB. Progressive familial intrahepatic cholestasis. J. Coll. Physicians Surg. Pak. 16: 673-675 (2006).

• Mitzner SR, Stange J, Peszynski P, Klammt S. Extracorporeal support of the failing liver. Curr. Opin. Crit. Care 8: 171-177 (2002).

• Miyachi K, Shibata M, Hasegawa C, Onozuka Y, Fritzler MJ. A case of primary biliary cirrhosis patient with anti-p97/VCP antibodies presenting a mild clinical course. Rinsho Byori 53: 19-23 (2005).

• Modi BP, Suh MY, Jonas MM, Lillehei C, Kim HB. Ileal exclusion for refractory symptomatic cholestasis in Alagille syndrome. J. Pediatr. Surg. 42: 800-805 (2007).

• Mohammed R, Goh KL, Wong NW. Primary biliary cirrhosis - experience in University Hospital, Kuala Lumpur. Med. J. Malaysia 51: 99-102 (1996).

• Montero JL, Pozo JC, Barrera P, Fraga E, Costan G, Dominguez JL, Muntane J, Rodriguez-Ariza A, Pleguezuelo M, Rufian S, Lopez-Cillero P, de la Mata M. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). Transplant. Proc. 38: 2511-2513 (2006). *

• Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 20: 1437-1441 (1994).

• Moran S, Rodriguez-Leal G, Marin-Lopez E, Arista J, Poo JL, Vargas-Vorackova F, Kershenobich D, Uribe M. Primary biliary cirrhosis: clinical features and survival of a Mexican population. Rev. Gastroenterol. Mex. 61: 212-219 (1996).

• Moreno-Otero R, Lisker-Melman M, Jones EA. Primary biliary cirrhosis. Med. Clin. North Am. 73: 911-929 (1989).

• Morton DH, Salen G, Batta AK, Shefer S, Tint GS, Belchis D, Shneider B, Puffenberger E, Bull L, Knisely AS. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol. Gastroenterology 119: 188-195 (2000). *

• Moses S. Pruritus. Am. Fam. Physician 68: 1135-1142 (2003). *

• Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J. Gastroenterol. 14: 7068-7074 (2008). *

• Mullally BA, Hansen WF. Intrahepatic cholestasis of pregnancy: review of the literature. Obstet. Gynecol. Surv. 57: 47-52 (2002).

• Mullhaupt B, Kullak-Ublick GA, Ambuhl PM, Stocker R, Renner EL. Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus. Hepatol. Res. 25: 442-446 (2003).

• Muratori P, Granito A, Pappas G, Muratori L, Lenzi M, Bianchi FB. Autoimmune liver disease 2007. Mol. Aspects Med. 29: 96-102 (2007).

• Muting D, Fischer R, Kalk JF, Kruck P. Chronic destructive non-suppurating cholangitis. Fortschr. Med. 100: 1179-1187 (1982).

• Nagasaka H, Yorifuji T, Hirano K, Ota A, Toyama-Nakagawa Y, Takatani T, Tsukahara H, Kobayashi K, Takayanagi M, Inomata Y, Uemoto S, Miida T. Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis. Metabolism 58: 48-54 (2009). *

• Nakano T, Inoue K, Hirohara J, Arita S, Higuchi K, Omata M, Toda G. Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC). Hepatol. Res. 22: 250-260 (2002).

• Nammour FE, Fayad NF, Peikin SR. Metformin-induced cholestatic hepatitis. Endocr. Pract. 9: 307-309 (2003).

• Narkewicz MR, Smith D, Gregory C, Lear JL, Osberg I, Sokol RJ. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J. Pediatr. Gastroenterol. Nutr. 26: 49-55 (1998). *

• Navasa M, Forns X, Sanchez V, Andreu H, Marcos V, Borras JM, Rimola A, Grande L, Garcia-Valdecasas JC, Granados A, Rodes J. Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrhosis after liver transplantation. J. Hepatol. 25: 129-134 (1996). *

• Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R, Rodriguez MJ, Chase V, Jeffers L, Schiff E. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am. J. Gastroenterol. 97: 2117-2119 (2002). *

• Neuberger J. Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. J. Hepatol. 39: 142-148 (2003). *

• Neuberger J. Drug-induced jaundice. Baillieres Clin. Gastroenterol. 3: 447-466 (1989).

• Neuberger J. Primary sclerosing cholangitis: indications for transplantation and recurrence. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 93-94. October 15-16 (2003). *

• Neuberger J. Liver transplantation for cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 113-121 (2003).

• Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur. J. Gastroenterol. Hepatol. 13: 1393-1394 (2001).

• Neuberger J, Portmann B, Macdougall BR, Calne RY, Williams R. Recurrence of primary biliary cirrhosis after liver transplantation. N. Engl. J. Med. 306: 1-4 (1982).

• Newton JA, Singh AK, Greaves MW, Spry CJ. Aquagenic pruritus associated with the idiopathic hypereosinophilic syndrome. Br. J. Dermatol. 122: 103-106 (1990).

• Newton JL, Bhala N, Burt J, Jones DE. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J. Hepatol. 44: 776-783 (2006). *

• Ng VL, Balistreri WF. Treatment options for chronic cholestasis in infancy and childhood. Curr. Treat. Options Gastroenterol. 8: 419-430 (2005).

• Ng VL, Ryckman FC, Porta G, Miura IK, de Carvalho E, Servidoni MF, Bezerra JA, Balistreri WF. Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 30: 152-156 (2000). *

• Nichols AA. Cholestasis of pregnancy: a review of the evidence. J. Perinat. Neonatal Nurs. 19: 217-225 (2005).

• Nielsen IM, Eiberg H. Cholestasis Familiaris Groenlandica: an epidemiological, clinical and genetic study. Int. J. Circumpolar Health 63 Suppl. 2: 192-194 (2004).

• Nikkels AF, Gillard P, Pierard GE. Etanercept in therapy multiresistant overlapping pityriasis lichenoides. J. Drugs Dermatol. 7: 990-992 (2008).

• Nir A, Sorokin Y, Abramovici H, Theodor E. Pregnancy and primary biliary cirrhosis. Int. J. Gynaecol. Obstet. 28: 279-282 (1989).

• Nishio A, Bass NM, Luketic VA, Coppel RL, Gershwin ME. Primary biliary cirrhosis: from induction to destruction. Semin. Gastrointest. Dis. 12: 89-102 (2001).

• No authors listed. The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. J. Hepatol. 17: 227-235 (1993).

• Nobili V. Mycophenolate mofetil in pediatric liver transplant patients with renal dysfunction: preliminary data. Pediatr. Transplant. 7: 454-457 (2003).

• Noiles K, Vender R. Treatment of severe facial psoriasis with adalimumab. J. Drugs Dermatol. 7: 1165-1167 (2008).

• Nordal EJ, Os I. Uremic pruritus - pathogenesis and treatment. Tidsskr. Nor. Laegeforen. 127: 1201-1203 (2007).

• Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J. Am. Acad. Dermatol. 54: S139-S142 (2006).

• Novelli G, Rossi M, Poli L, Predagostini R, Iappelli M, Morabito V, Lai Q, Novelli L, Mennini G, Corradini SG, Berloco PB. Intractable pruritus in patients with hepatitis C virus. Transplant. Proc. 38: 1089-1091 (2006). *

• Nunes AC, Amaro P, Mac as F, Cipriano A, Martins I, Rosa A, Pimenta I, Donato A, Freitas D. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report. Eur. J. Gastroenterol. Hepatol. 13: 279-282 (2001).

• O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 14: 838-847 (1991).

• O'Donohue JW, Pereira SP, Ashdown AC, Haigh CG, Wilkinson JR, Williams R. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment. Pharmacol. Ther. 21: 1041-1045 (2005). *

• O'Keeffe C, Baird AW, Nolan N, McCormick PA. Cholestatic pruritus - the role of cutaneous mast cells and nerves. Aliment. Pharmacol. Ther. 19: 1293-1300 (2004). *

• Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung 54: 809-829 (2004).

• Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumura Y, Kamimura T, Ohta Y, Tsuji T, Hattori N, Namihisa T, et al. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol. Jpn. 25: 774-780 (1990).

• Olasz EB, Yancey KB. Bullous pemphigoid and related subepidermal autoimmune blistering diseases. Curr. Dir. Autoimmun. 10: 141-166 (2008).

• Olsson R, Broome U, Danielsson A, Hagerstrand I, Jarnerot G, Loof L, Prytz H, Ryden BO. Spontaneous course of symptoms in primary sclerosing cholangitis: relationships with biochemical and histological features. Hepatogastroenterology 46: 136-141 (1999).

• Olsson RG, Asztely MS. Prognostic value of cholangiography in primary sclerosing cholangitis. Eur. J. Gastroenterol. Hepatol. 7: 251-254 (1995).

• Oo YH, Neuberger J. Options for treatment of primary biliary cirrhosis. Drugs 64: 2261-2271 (2004).

• Ott P, Vilstrup H. Hepatic pruritis. Ugeskr. Laeger. 168: 776-779 (2006).

• Owczarek D, Garlicka M, Pierzchala-Koziec K, Skulina D, Szulewski P. Met-enkephalin plasma concentration and content in liver tissue in patients with primary biliary cirrhosis. Przegl. Lek. 60: 461-466 (2003).

• Ozcan H, Seyhan M, Yologlu S. Is metronidazole 0.75% gel effective in the treatment of seborrhoeic dermatitis? A double-blind, placebo controlled study. Eur. J. Dermatol. 17: 313-316 (2007).

• Palazzi C, D'Amico E, Cacciatore P, Pennese E, Olivieri I. Non-rheumatoid erosive arthritis associated with type I hereditary angioedema. Clin. Rheumatol. 24: 632-633 (2005). *

• Palma J, Reyes H, Ribalta J, Hernandez I, Sandoval L, Almuna R, Liepins J, Lira F, Sedano M, Silva O, Toha D, Silva JJ. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J. Hepatol. 27: 1022-1028 (1997). *

• Palma J, Reyes H, Ribalta J, Iglesias J, Gonzalez M, Hernandez I, Alvarez C, Molina C, Danitz AM. Effects of ursodeoxycholic acid in patients with cholestasis of pregnancy. Rev. Med. Chil. 119: 169-171 (1991).

• Palmer DG, Eads J. Intrahepatic cholestasis of pregnancy: a critical review. J. Perinat. Neonatal. Nurs. 14: 39-51 (2000).

• Panther E, Blum HE. Liver diseases in pregnancy. Dtsch. Med. Wochenschr. 133: 2283-2287 (2008).

• Papachristou GI, Demetris AJ, Craig F, Lee KKW, Rabinovitz M. Cholestatic jaundice and bone lesions in an elderly woman. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 53-57 (2004). *

• Pares A, Cisneros L, Salmeron JM, Caballeria L, Mas A, Torras A, Rodes J. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 99: 1105-1110 (2004). *

• Pares A, Rodes J. Treatment of primary biliary cirrhosis. Minerva Gastroenterol. Dietol. 46: 165-174 (2000).

• Pastar Z, Lipozencic J, Ljubojevic S. Etiopathogenesis of atopic dermatitis - an overview. Acta Dermatovenerol. Croat. 13: 54-62 2005.

• Patel SD, Taylor HC. Intrahepatic cholestasis during nicotinic acid therapy. Cleve. Clin. J. Med. 61: 70-75 (1994).

• Patel T, Ishiuji Y, Yosipovitch G. Nocturnal itch: why do we itch at night? Acta Derm. Venereol. 87: 295-298 (2007). *

• Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, Risler T, Berger ED, Kuhlmann U, Mettang T. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J. Am. Soc. Nephrol. 11: 514-519 (2000). *

• Paus R, Schmelz M, Biro T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J. Clin. Invest. 116: 1174-1186 (2006). *

• Paus TC, Schneider G, Van De Vondel P, Sauerbruch T, Reichel C. Diagnosis and therapy of intrahepatic cholestasis of pregnancy. Z. Gastroenterol. 42: 623-628 (2004).

• Pausch J, Gatzen M. Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins? Internist (Berl.) 47: 1239-1244 (2006).

• Peck LW, Monsen ER, Ahmad S. Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. Am. J. Clin. Nutr. 64: 210-214 (1996). *

• Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, laina A. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 348: 1552-1554 (1996). *

• Perdigoto R, Wiesner RH. Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. Gastroenterology 102: 1389-1391 (1992).

• Perez Fernandez T, Lopez Serrano P, Tomas E, Gutierrez M, Lledo J, Cacho G, Santander C, Fernandez Rodriguez C. Diagnostic and therapeutic approach to cholestatic liver disease. Rev. Esp. Enferm. Dig. 96: 60-73 (2004).

• Peters MG, Di Bisceglie AM, Kowdley KV, Flye NL, Luketic VA, Munoz SJ, Garcia-Tsao G, Boyer TD, Lake JR, Bonacini M, Combes B; PUMPS Group. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology 46: 769-775 (2007). *

• Pettigrew HD, Teuber SS, Kong JS, Gershwin ME. Contemporary challenges in mastocytosis. Clin. Rev. Allergy Immunol. Jul 29 [Epub ahead of print] (2009). *

• Pfeiffer C. Dermatitis herpetiformis: a clinical chameleon. Hautarzt. 57: 1021-1029 (2006).

• Pham TH, Kaushik S, Lin BP, Jones DB. Case report: acanthosis nigricans in association with primary biliary cirrhosis: resolution after liver transplantation. J. Gastroenterol. Hepatol. 11: 1021-1023 (1996).

• Phillips WG. Pruritus. What to do when the itching won't stop. Postgrad. Med. 92: 34-6, 39-40, 43-46 (1992).

• Pincon JA, Chatelain P, Mallet-Guy Y, Bouvier R, de Parscau L, Francois R. Byler's disease. Ultrastructural study. Apropos of a case in an infant. Pediatrie. 39: 279-288 (1984).

• Pitche PT. Pellagra. Sante 15: 205-208 (2005).

• Placer C, Elosegui JL, Irureta I, Mujika JA, Goena I, Enriquez Navascues JM. Initial response to topical diltiazem can predict outcome of chronic anal fissure. Cir. Esp. 82: 16-20 (2007).

• Podesta A, Lopez P, Terg R, Villamil F, Flores D, Mastai R, Udaondo CB, Companc JP. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig. Dis. Sci. 36: 216-220 (1991).

• Podymova SD, Nadinskaia MIu. Clinical trial of heptral in patients with chronic diffuse liver disease with intrahepatic cholestasis syndrome. Klin. Med. (Mosk.) 76: 45-48 (1998).

• Poindexter G, Morrell DS. Anogenital pruritus: lichen sclerosus in children. Pediatr. Ann. 36: 785-791 (2007).

• Polat M, Lenk N, Yalcin B, Gur G, Tamer E, Artuz F, Alli N. Efficacy of erythromycin for psoriasis vulgaris. Clin. Exp. Dermatol. 32: 295-297 (2007). *

• Ponsioen CY, Lam K, van Milligen de Wit AW, Huibregtse K, Tytgat GN. Four years experience with short term stenting in primary sclerosing cholangitis. Am. J. Gastroenterol. 94: 2403-2407 (1999). *

• Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16 (2005). *

• Portmann BC. Primary biliary cirrhosis and sclerosing cholangitis. Current Diagnostic Pathology 8: 133-143 (2002). *

• Potasman I, Heinrich I, Bassan HM. Aquagenic pruritus: prevalence and clinical characteristics. Isr. J. Med. Sci. 26: 499-503 (1990).

• Poupon R. Treatment of primary biliary cirrhosis and overlap syndromes: current standards. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 77-78 (2004). *

• Poupon R. Primary biliary cirrhosis: a 2010 update. J. Hepatol. [In Press] (2010).

• Poupon R, Chazouilleres O, Balkau B, Poupon RE. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group. J. Hepatol. 30: 408-412 (1999). *

• Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1: 834-836 (1987).

• Poupon RE, Balkau B, Guechot J, Heintzmann F. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. Hepatology 19: 635-640 (1994).

• Poupon RE, Eschwege E, Poupon R. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J. Hepatol. 11: 16-21 (1990).

• Poveda-Roda R, Bagan JV, Jimenez-Soriano Y, Diaz-Fernandez JM, Gavalda-Esteve C. Retinoids and proliferative verrucous leukoplakia (PVL). A preliminary study. Med. Oral Patol. Oral Cir. Bucal. Aug 13 [Epub ahead of print] (2009).

• Prakash BV, Sirisha NL, Satyanarayana VV, Sridevi L, Ramachandra BV. Aetiopathological and clinical study of erythroderma. J. Indian Med. Assoc. 107: 100, 102-103 (2009).

• Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 21: 270-274 (2005). *

• Price TJ, Patterson WK, Olver IN. Rifampicin as treatment for pruritus in malignant cholestasis. Support Care Cancer 6: 533-535 (1998).

• Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123: 1044-1051 (2002). *

• Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 50: 436-439 (2002). *

• Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol. Physiol. 21: 75-80 (2008).

• Puri AS, Kumar N, Gondal R, Lamba GS, Jain M. Primary biliary cirrhosis: an Indian experience. Indian J. Gastroenterol. 20: 28-29 (2001).

• Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J. Rare Dis. 2: 26 (2007). *

• Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin. Rev. Allergy Immunol. 28: 147-158 (2005). *

• Pusl T, Denk GU, Parhofer KG, Beuers U. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J. Hepatol. 45: 887-891 (2006). *

• Qureshi WA. Intrahepatic cholestatic syndromes: pathogenesis, clinical features and management. Dig. Dis. 17: 49-59 (1999).

• Rabinovitz M, Gavaler JS, Schade RR, Dindzans VJ, Chien MC, Van Thiel DH. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 11: 7-11 (1990).

• Rados J, Marinovic Kulisic S, Lipozencic J, Budimcic D, Loncaric D. Macular amyloidosis: a case report. Acta Dermatovenerol. Croat. 16: 138-141 (2008).

• Raedsch R, Stiehl A, Walker S, Scherrmann JM, Kommerell B. Combined ursodeoxycholic acid plus colchicine - treatment of primary biliary cirrhosis: results of a placebo-controlled double-blind study. Z. Gastroenterol. 30 Suppl. 1: 55-57 (1992).

• Raiford DS. Pruritus of chronic cholestasis. QJM 88: 603-607 (1995).

• Rallis E, Anyfantakis V. Coexistent psoriasis and bullous pemphigoid responding to mycophenolate mofetil monotherapy. Skinmed. 7: 101-102 (2008). *

• Ramanathan M, Abidin MN, Muthukumarappan M. The prevalence of skin manifestations in thyrotoxicosis - a retrospective study. Med. J. Malaysia 44: 324-328 (1989).

• Ramos R, Mascarenhas J, Duarte P, Vicente C, Casteleiro C. Conjugated linoleic acid-induced toxic hepatitis: first case report. Dig. Dis. Sci. 54: 1141-1143 (2009). *

• Rashtak S, Pittelkow MR. Skin involvement in systemic autoimmune diseases. Curr. Dir. Autoimmun. 10: 344-358 (2008).

• Raslan HM, Ezzat WM, Abd El Hamid MF, Emam H, Amre KS. Skin manifestations of chronic hepatitis C virus infection in Cairo, Egypt. East. Mediterr. Health J. 15: 692-700 (2009).

• Rebhandl W, Felberbauer FX, Huber WD, Puig S, Paya K, Rauhofer U, Saadi S, Aberle J, Horcher E. Progressive familial intrahepatic cholestasis (Byler disease): current genetics and therapy. Klin. Padiatr. 212: 64-70 (2000).

• Reddy L, Krajnik M, Zylicz Z. Transdermal buprenorphine may be effective in the treatment of pruritus in primary biliary cirrhosis. J. Pain Symptom Manage. 34: 455-456 (2007).

• Reesink HW, Weegink CJ. New hope for a cure for chronic hepatitis C. J. Hepatol. 51: 835-837 (2009).

• Reggiani A, Dizioli P, Quattrocchi D, Quinzani M, Marelli A, Bodini P. Intrahepatic cholestasis: clinical and nosological classification. Critical survey of personal experience. Minerva Gastroenterol. Dietol. 43: 71-81 (1997).

• Reich A, Orda A, Wi Nicka B, Szepietowski JC. Plasma neuropeptides and perception of pruritus in psoriasis. Acta Derm. Venereol. 87: 299-304 (2007). *

• Reich A, Szepietowski JC. Mediators of pruritus in psoriasis. Mediators Inflamm. 2007: 64727 (2007). *

• Reichel C, Meier-Abt PJ. Cholestatic liver diseases. Ther. Umsch. 54: 639-644 (1997).

• Reichen J. Drug treatment of cholestatic liver diseases. Ther. Umsch. 49: 315-325 (1992).

• Remmel T, Remmel H, Salupere V. Aminoterminal propeptide of type III procollagen and hyaluronan in patients with primary biliary cirrhosis: markers of fibrosis in primary biliary cirrhosis. J. Gastroenterol. Hepatol. 11: 1016-1020 (1996).

• Reyes H. The spectrum of liver and gastrointestinal disease seen in cholestasis of pregnancy. Gastroenterol. Clin. North Am. 21: 905-921 (1992).

• Reyes H. Review: intrahepatic cholestasis. A puzzling disorder of pregnancy. J. Gastroenterol. Hepatol. 12: 211-216 (1997).

• Reyes H, Simon FR. Intrahepatic cholestasis of pregnancy: an estrogen-related disease. Semin. Liver Dis. 13: 289-301 (1993).

• Reyes H, Sjovall J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann. Med. 32: 94-106 (2000).

• Reynoso-Paz S, Coppel RL, Nakanuma Y, Gershwin ME. Primary biliary cirrhosis. Connecting molecular biology to clinical medicine. Clin. Rev. Allergy Immunol. 18: 241-262 (2000).

• Ribalta J, Reyes H, Gonzalez MC, Iglesias J, Arrese M, Poniachik J, Molina C, Segovia N. S-Adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology 13: 1084-1089 (1991).

• Ricci P, Hofmann AF, Hagey LR, Jorgensen RA, Rolland Dickson E, Lindor KD. Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. Dig. Dis. Sci. 43: 1292-1295 (1998). *

• Riely CA, Bacq Y. Intrahepatic cholestasis of pregnancy. Clin. Liver Dis. 8: 167-176 (2004).

• Rifai K. Extracorporeal albumin dialysis. Hepatol. Res. 38 (s1: The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28-29 September 2007, Iwate, Japan): S41-S45 (2008). *

• Rifai K, Hafer C, Rosenau J, Thmann CA, Haller H, Manns MP, Fliser D. Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus). Scand. J. Gastroenterol. 41: 1212-1217 (2006). *

• Rifai K, Manns MP. Review article: clinical experience with Prometheus. Ther. Apher. Dial. 10: 132-137 (2006).

• Rifle G, Mousson C, Hillon P, Marceau M, Chalopin JM, Tanter Y. Primary biliary cirrhosis: therapeutic trial using plasma exchange and immunosuppression. Preliminary results. Ann. Med. Interne (Paris) 139 Suppl. 1: 32-34 (1988).

• Ring J, Mohrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 31: 185-198 (2008).

• Roguedas AM, Crespel E, Kupfer I, De Saint Martin L, Misery L, Sassolas B. Bullous pemphigoid sparing acquired lymphedema. Ann. Dermatol. Venereol. 133: 250-252 (2006).

• Roncaglia N, Locatelli A, Arreghini A, Assi F, Cameroni I, Pezzullo JC, Ghidini A. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG 111: 17-21 (2004).

• Rosenthal P. Digestive disease week 2000. American association for the study of liver diseases. IDrugs 3: 868-871 (2000).

• Rossiello L, Palla M, Aiello FS, Baroni A, Satriano RA. Granuloma faciale with extrafacial lesions. Skinmed. 6: 150-151 (2007).

• Rost D, Kulaksiz H, Stiehl A. Treatment of primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 10: 111-119 (2007).

• Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch. Intern. Med. 164: 2017-2023 (2004). *

• Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann. Intern. Med. 121: 207-218 (1994). *

• Rudi J, Schonig T, Stremmel W. Therapy with ursodeoxycholic acid in primary biliary cirrhosis in pregnancy. Z. Gastroenterol. 34: 188-191 (1996).

• Rudzki C, Ishak KG, Zimmerman HJ. Chronic intrahepatic cholestasis of sarcoidosis. Am. J. Med. 59: 373-387 (1975).

• Rust C, Sauter GH, Oswald M, Buttner J, Kullak-Ublick GA, Paumgartner G, Beuers U. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur. J. Clin. Invest. 30: 135-139 (2000).

• Rusu EE, Voiculescu M, Zilisteanu DS, Ismail G. Molecular adsorbents recirculating system in patients with severe liver failure. Experience of a single Romanian centre. J. Gastrointestin. Liver Dis. 18: 311-316 (2009). *

• Rutherford AE, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 22: 209-214 (2006). *

• Sadri N, Schneider RJ. Auf1/Hnrnpd-deficient mice develop pruritic inflammatory skin disease. J. Invest. Dermatol. 129: 657-670 (2009). *

• Sahagun Flores JE, Soto Ortiz JA, Tovar Mendez CE, Cardenas Ochoa EC, Hernandez Flores G. Síndrome de Stevens Johnson mas colestasis intrahepatica inducido por clindamicina o clorfeniramina. Dermatol. Online J. 15: 12 (2009).

• Saich R, Collins P, Ala A, Standish R, Hodgson H. Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis. Eur. J. Gastroenterol. Hepatol. 17: 585-588 (2005).

• Saka B, Kalayoglu-Besisik S, Ozturk GB, Dogan O, Erten N. Primary biliary cirrhosis and IgG-kappa type multiple myeloma both respond well to vincristine, adriamycin and dexamethasone: is there a pathogenic relationship? J. Formos. Med. Assoc. 107: 185-190 (2008). *

• Sakauchi F, Mori M, Zeniya M, Toda G. Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. J. Epidemiol. 16: 30-34 (2006). *

• Sakauchi F, Mori M, Zeniya M, Toda G. A cross-sectional study of primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. J. Epidemiol. 15: 24-28 (2005). *

• Saleh MM, Abdo KR. Intrahepatic cholestasis of pregnancy: review of the literature and evaluation of current evidence. J. Womens Health (Larchmt.) 16: 833-841 (2007).

• Salen G, Batta AK. Bile acid abnormalities in cholestatic liver diseases. Gastroenterol. Clin. North Am. 28: 173-193 (1999).

• Sandhu BS, Luketic VA. Management of primary sclerosing cholangitis. Gastroenterology & Hepatology 2: 843-849 (2006). *

• Sangorrin Iranzo A, Iriondo Sanz M, Alvarez Garcia L, Jara Vega P, Martin de Carpi J. Progressive familial intrahepatic cholestasis presenting as liver failure. An. Pediatr. (Barc.) 71: 510-513 (2009).

• Sarin SK, Monga R, Sandhu BS, Sharma BC, Sakhuja P, Malhotra V. Primary biliary cirrhosis in India. Hepatobiliary Pancreat. Dis. Int. 5: 105-109 (2006). *

• Saritas U, Aydin B, Ustundag Y. Plasmapheresis and corticosteroid treatment for persistent jaundice after successful drainage of common bile duct stones by endoscopic retrograde cholangiography. World J. Gastroenterol. 13: 4152-4153 (2007). *

• Sasaki H, Inoue K, Higuchi K, Yasuyama T, Koyata H, Kuroki T, Yamamoto S, Ichida F. Primary biliary cirrhosis in Japan: national survey by the Subcommittee on Autoimmune hepatitis. Gastroenterol. Jpn. 20: 476-485 (1985).

• Schirrmacher S, Blumenstein I, Stein J. Pathogenesis and treatment of pruritus in patients with cholestasis. Z. Gastroenterol. 41: 259-262 (2003).

• Schneider G, Paus TC, Kullak-Ublick GA, Meier PJ, Wienker TF, Lang T, van de Vondel P, Sauerbruch T, Reichel C. Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy. Hepatology 45: 150-158 (2007). *

• Schreibman I, Regev A. Recurrent primary biliary cirrhosis after liver transplantation - the disease and its management. MedGenMed. 8: 30 (2006). *

• Schumann R, Hudcova J. Cholestasis of pregnancy, pruritus and 5-hydroxytryptamine 3 receptor antagonists. Acta Obstet. Gynecol. Scand. 83: 861-862 (2004).

• Schumann R, Zabala L, Angelis M, Bonney I, Tighiouart H, Carr DB. Altered hematologic profiles following donor right hepatectomy and implications for perioperative analgesic management. Liver Transpl. 10: 363-368 (2004). *

• Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 61: 33-37 (1995). *

• Seckin D, Demircay Z, Akin O. Generalized pruritus treated with narrowband UVB. Int. J. Dermatol. 46: 367-370 (2007). *

• Sedlack RE, Smyrk TC, Czaja AJ, Talwalkar JA. Celiac disease-associated autoimmune cholangitis. Am. J. Gastroenterol. 97: 3196-3198 (2002). *

• Seitz CS, Garbaraviciene J, Brocker EB, Hamm H. Superimposed linear psoriasis: differential therapeutic response of linear and nonlinear lesions. Clin. Exp. Dermatol. 34: e177-e179 (2009). *

• Selmi C, Lleo A, Invernizzi P, Gershwin ME. Chapter 18. Primary biliary cirrhosis and autoimmune cholangitis. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 235-248 (2007). *

• Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am. J. Gastroenterol. 100: 468-475 (2005). *

• Sentilhes L, Bacq Y. Intrahepatic cholestasis of pregnancy. J. Gynecol. Obstet. Biol. Reprod. (Paris) 37: 118-126 (2008).

• Shalev SA, Sprecher E, Indelman M, Hujirat Y, Bergman R, Rottem M. A novel missense mutation in CIAS1 encoding the pyrin-like protein, cryopyrin, causes familial cold autoinflammatory syndrome in a family of Ethiopian origin. Int. Arch. Allergy Immunol. 143: 190-193 (2007).

• Sharma BC, Saraswat VA, Choudhuri G, Das A, Ghoshal UC, Pandey R. Primary biliary cirrhosis without pruritus - an Indian variant. Trop. Gastroenterol. 17: 176-177 (1996).

• Sherlock S. Primary biliary cirrhosis: critical evaluation and treatment policies. Scand. J. Gastroenterol. Suppl. 77: 63-74 (1982).

• Sherlock S. Primary biliary cirrhosis: clarifying the issues. Am. J. Med. 96: 27S-33S (1994).

• Shi J, Li Z, Zeng X, Lin Y, Xie WF. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol. Res. 39: 865-873 (2009). *

• Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie W. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am. J. Gastroenterol. 101: 1529-1538 (2006). *

• Shi X, Zhang C, Jia J, Zhang F, Qian L, Wang B. Histopathological features of 27 cases of primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 10: 338-340 (2002).

• Shin HJ, Chung JS, Choi YJ, Cho GJ. A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia. Am. J. Clin. Oncol. 32: 227-232 (2009).

• Shingai R, Maeda T, Onishi S, Yamamoto Y. Autoantibody against 70 kD heat shock protein in patients with autoimmune liver diseases. J. Hepatol. 23: 382-390 (1995). *

• Shneider BL. Progressive intrahepatic cholestasis: mechanisms, diagnosis and therapy. Pediatr. Transplant. 8: 609-612 (2004).

• Silva MO, Reddy KR, McDonald T, Jeffers LJ, Schiff ER. Danazol-induced cholestasis. Am. J. Gastroenterol. 84: 426-428 (1989).

• Silveira MG, Lindor KD. Primary sclerosing cholangitis. Can. J. Gastroenterol. 22: 689-698 (2008). *

• Simons FE, Watson WT, Minuk GY, Simons KJ. Cetirizine pharmacokinetics and pharmacodynamics in primary biliary cirrhosis. J. Clin. Pharmacol. 33: 949-954 (1993).

• Skiba G, Milkiewicz P, Mutimer D, Burns DA, Marsden JR, Elias E. Successful treatment of acquired perforating dermatosis with rifampicin in an Asian patient with sclerosing cholangitis. Liver 19: 160-163 (1999).

• Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 13: 1810-1815 (2007). *

• Song JC, Zhang MZ, Lu ZJ, Yang LQ, Song JG, Sun YM, Yu WF. The effects of obstructive jaundice on the pharmacodynamics of propofol: does the sensitivity of intravenous anesthetics change among icteric patients? Acta Anaesthesiol. Scand. 53: 1329-1335 (2009).

• Sorda J, Findor J. Methotrexate therapy in primary biliary cirrhosis. Acta Gastroenterol. Latinoam. 30: 221-225 (2000).

• Soy M, Piskin S. Cutaneous findings in patients with primary Sjogren's syndrome. Clin. Rheumatol. 26: 1350-1352 (2007). *

• Soza A, Riquelme F, Alvarez M, Duarte I, Glasinovic JC, Arrese M. Hepatotoxicity by amoxicillin/clavulanic acid: case report. Rev. Med. Chil. 127: 1487-1491 (1999).

• Spivey JR, Jorgensen RA, Gores GJ, Lindor KD. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 89: 2028-2032 (1994).

• Squires RH. End-stage liver disease in children. Curr. Treat. Options Gastroenterol. 4: 409-421 (2001).

• Stander S. Chronic pruritus: principals of diagnostics and therapy. Hautarzt. 58: 627-638 (2007).

• Stander S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T. Neurophysiology of pruritus: cutaneous elicitation of itch. Arch. Dermatol. 139: 1463-1470 (2003). *

• Stander S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, Bergasa NV, Gieler U, Misery L, Wallengren J, Darsow U, Streit M, Metze D, Luger TA, Greaves MW, Schmelz M, Yosipovitch G, Bernhard JD. Clinical classification of itch: a position paper of the international forum for the study of itch. Acta Derm. Venereol. 87: 291-294 (2007). *

• Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif. Organs 26: 103-110 (2002). *

• Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: current and future therapies. J. Hepatol. 52: 258-271 (2010). *

• Stapelbroek JM, van Erpecum KJ, Klomp LW, Venneman NG, Schwartz TP, van Berge Henegouwen GP, Devlin J, van Nieuwkerk CM, Knisely AS, Houwen RH. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 43: 51-53 (2006). *

• Stauber RE, Krisper P, Zollner G, Iberer F, Beuers U, Trauner M. Extracorporeal albumin dialysis in a patient with primary sclerosing cholangitis: effect on pruritus and bile acid profile. Int. J. Artif. Organs 27: 342-344 (2004).

• Steele IL, Levy C, Lindor KD. Primary sclerosing cholangitis - approach to diagnosis. MedGenMed. 9: 20 (2007). *

• Steig B, Juijn JA, Bull LN, Houwen RH, Tygstrup N. Recurrent familial intrahepatic cholestasis in the Faroe Islands. Ugeskr. Laeger. 161: 4871-4874 (1999).

• Steinman HK, Greaves MW. Aquagenic pruritus. J. Am. Acad. Dermatol. 13: 91-96 (1985).

• Stickel F, Droz S, Patsenker E, Bogli-Stuber K, Aebi B, Leib SL. Severe hepatotoxicity following ingestion of Herbalife((R)) nutritional supplements contaminated with Bacillus subtilis. J. Hepatol. 50: 111-117 (2009). *

• Stiehl A. Endoscopic interventions in the biliary tract. Curr. Treat. Options Gastroenterol. 6: 87-92 (2003).

• Stiehl A. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Ital. J. Gastroenterol. 28: 178-180 (1996).

• Stiehl A. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis. Scand. J. Gastroenterol. Suppl. 204: 59-61 (1994).

• Stiehl A, Rudolph G, Raedsch R, Moller B, Hopf U, Lotterer E, Bircher J, Folsch U, Klaus J, Endele R, et al. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 12: 492-497 (1990).

• Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J. Hepatol. 20: 57-64 (1994).

• Stockbrugger RW, Olsson R, Jaup B, Jensen J. Forty-six patients with primary sclerosing cholangitis: radiological bile duct changes in relationship to clinical course and concomitant inflammatory bowel disease. Hepatogastroenterology 35: 289-294 (1988).

• Stocker C, Hardmeier B, Looser M, Scharf C, Greminger P. Cholestatic jaundice and pruritus. Schweiz. Rundsch. Med. Prax. 91: 1561-1564 (2002).

• Strassburg CP. Autoimmune liver diseases. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 66-70 (2005). *

• Sturm E, Franssen CF, Gouw A, Staels B, Boverhof R, De Knegt RJ, Stellaard F, Bijleveld CM, Kuipers F. Extracorporal albumin dialysis (MARS) improves cholestasis and normalizes low apo A-I levels in a patient with benign recurrent intrahepatic cholestasis (BRIC). Liver 22 Suppl. 2: 72-75 (2002).

• Su CW, Wu JC, Chiou YY, Tsay SH, Huo TI, Huang YH, Hung HH, Lin HC, Lee SD. Successful radiofrequency ablation therapy for hepatocellular carcinoma in a male patient with early stage primary biliary cirrhosis and positive serum hepatitis B core antibody. J. Chin. Med. Assoc. 71: 40-44 (2008).

• Subramaniam P, Clayton PT, Portmann BC, Mieli-Vergani G, Hadzic N. Variable clinical spectrum of the most common inborn error of bile acid metabolism - 3beta-hydroxy-Delta5-C27-steroid dehydrogenase deficiency. J. Pediatr. Gastroenterol. Nutr. 50: 61-66 (2010).

• Sudan DL, Shaw BW Jr. The role of liver transplantation in the management of portal hypertension. Clin. Liver Dis. 1: 115-120, xii (1997).

• Sugimoto M, Arai I, Futaki N, Hashimoto Y, Honma Y, Nakaike S. COX-1 inhibition enhances scratching behaviour in NC/Nga mice with atopic dermatitis. Exp. Dermatol. 15: 582-588 (2006). *

• Sugimoto M, Arai I, Futaki N, Hashimoto Y, Honma Y, Nakaike S. Increased scratching counts depend on a decrease in ability of cutaneous prostaglandin D2 biosynthesis in NC/Nga mice with atopic dermatitis. Exp. Dermatol. 14: 898-905 (2005). *

• Sugimoto M, Arai I, Futaki N, Hashimoto Y, Sakurai T, Honma Y, Nakaike S. The anti-pruritic efficacy of TS-022, a prostanoid DP1 receptor agonist, is dependent on the endogenous prostaglandin D2 level in the skin of NC/Nga mice. Eur. J. Pharmacol. 564: 196-203 (2007). *

• Sullivan JR, Watson A. Naltrexone: a case report of pruritus from an antipruritic. Australas. J. Dermatol. 38: 196-198 (1997).

• Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 448: 700-703 (2007). *

• Sundaram SS, Bove KE, Lovell MA, Sokol RJ. Mechanisms of disease: inborn errors of bile acid synthesis. Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 456-468 (2008).

• Sundaram SS, Sokol RJ. The multiple facets of ABCB4 (MDR3) deficiency. Curr. Treat. Options Gastroenterol. 10: 495-503 (2007).

• Surrenti C, Pozzi M, Biagini MR, Franco C, Lombardo R, Avanzi G. Effects of plasma exchange (PE) in primary biliary cirrhosis (PBC). A pilot study. Hepatogastroenterology 37: 128-130 (1990).

• Swain MG. Pathogenesis of fatigue and pruritus in cholestatic liver disease. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 33. October 15-16 (2003). *

• Szalay F. Treatment of primary biliary cirrhosis. J. Physiol. Paris 95: 407-412 (2001).

• Szekely H, Ponyai G, Temesvari E, Berczi L, Harsing J, Karpati S, Herszenyi L, Tulassay Z, Juhasz M. Association of collagenous colitis with prurigo nodularis. Eur. J. Gastroenterol. Hepatol. 21: 946-951 (2009).

• Szepetiuk G, Melotte C, Pierard-Franchimont C, Quatresooz P, Pierard GE. How I explore...pruritus in a pregnant woman. Rev. Med. Liege. 62: 719-724 (2007).

• Szepietowski JC, Reich A, Wisnicka B. Pruritus and psoriasis. Br. J. Dermatol. 151: 1284 (2004). *

• Takahashi A, Hasegawa M, Sumazaki R, Suzuki M, Toki F, Suehiro T, Onigata K, Tomomasa T, Suzuki T, Matsui A, Morikawa A, Kuwano H. Gradual improvement of liver function after administration of ursodeoxycholic acid in an infant with a novel ABCB11 gene mutation with phenotypic continuum between BRIC2 and PFIC2. Eur. J. Gastroenterol. Hepatol. 19: 942-946 (2007).

• Talwalkar JA, Souto E, Jorgensen RA, Lindor KD. Natural history of pruritus in primary biliary cirrhosis. Clin. Gastroenterol. Hepatol. 1: 297-302 (2003). *

• Tan EK, Millington GW, Levell NJ. Acupuncture in dermatology: an historical perspective. Int. J. Dermatol. 48: 648-652 (2009).

• Tan LK. Obstetric cholestasis: current opinions and management. Ann. Acad. Med. Singapore 32: 294-298 (2003).

• Tanaka T, Ishii K, Suzuki H, Kameyoshi Y, Hide M. Cholinergic urticaria successfully treated by immunotherapy with partially purified sweat antigen. Arerugi. 56: 54-57 (2007).

• Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am. J. Gastroenterol. 102: 1528-1536 (2007). *

• Tavian D, Degiorgio D, Roncaglia N, Vergani P, Cameroni I, Colombo R, Coviello DA. A new splicing site mutation of the ABCB4 gene in intrahepatic cholestasis of pregnancy with raised serum gamma-GT. Dig. Liver Dis. 41: 671-675 (2009).

• Tennyson H, Levine N. Neurotropic and psychotropic drugs in dermatology. Dermatol. Clin. 19: 179-197, x (2001).

• ter Borg PC, van Buuren HR, Visser W. Intrahepatic cholestasis of pregnancy. Ned. Tijdschr. Geneeskd. 147: 1056-1059 (2003).

• Teran A, Fabrega E, Pons-Romero F. Pruritus associated with cholestasis. Gastroenterol. Hepatol. Oct 14 [Epub ahead of print] (2009).

• Terasaki S, Nakanuma Y, Hoso M, Ogino H, Unoura M, Kobayashi K, Mizuno Y, Nakagawa H, Shimizu M, Kanai M, et al. Three cases of primary biliary cirrhosis associated with bronchial asthma. J. Gastroenterol. 30: 667-671 (1995).

• Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J. Hepatol. 37: 717-722 (2002). *

• Terra SG, Tsunoda SM. Opioid antagonists in the treatment of pruritus from cholestatic liver disease. Ann. Pharmacother. 32: 1228-1230 (1998).

• Tervaert JW, Van Hoek B, Koek G. Antineutrophil cytoplasmic antibodies in small-duct primary sclerosing cholangitis. Gastroenterology 136: 364 (2009). *

• Textor HJ, Flacke S, Pauleit D, Keller E, Neubrand M, Terjung B, Gieseke J, Scheurlen C, Sauerbruch T, Schild HH. Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy 34: 984-990 (2002).

• Thompson R, Strautnieks S. BSEP: function and role in progressive familial intrahepatic cholestasis. Semin. Liver Dis. 21: 545-550 (2001). *

• Thompson RJ. The consequence of not being able to transport bile acids. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 60 (2006). *

• Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 297: 1501-1504 (1988). *

• Tlacuilo-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F, Soto-Ortiz A, Barba-Gomez F, Hernandez-Torres M, Salazar-Paramo M. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 44: 1564-1568 (2005). *

• Tomar BS. Infantile cholestasis - advances in its understanding: new concepts. Acta Paediatr. Taiwan 41: 6-12 (2000).

• Tomer G, Shneider BL. Disorders of bile formation and biliary transport. Gastroenterol. Clin. North Am. 32: 839-855, vi (2003).

• Tong MJ, Nies KM, Reynolds TB, Quismorio FP. Immunological studies in familial primary biliary cirrhosis. Gastroenterology 71: 305-307 (1976).

• Trauner M. The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope? Hepatology 40: 260-263 (2004). *

• Trauner M. Molecular mechanisms of cholestasis. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 64-65 (2005). *

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 19: 216-231 (2003).

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 20: 220-230 (2004). *

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 15: 217-228 (1999).

• Trauner M, Wagner M, Fickert P, Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J. Clin. Gastroenterol. 39: S111-S124 (2005).

• Tribe RM, Dann AT, Kenyon AP, Seed P, Shennan AH, Mallet A. Longitudinal profiles of 15 serum bile acids in patients with intrahepatic cholestasis of pregnancy. Am. J. Gastroenterol. Nov 10 [Epub ahead of print] (2009). *

• Triger DR. Autoimmune chronic active hepatitis and primary biliary cirrhosis. Baillieres Clin. Gastroenterol. 3: 21-38 (1989).

• Tsai CY, Huo AP, Chou CT, Wu TH, Tsai YY. Hepatitis, cholangitis, pulmonary hypertension, digital gangrene, and conjunctivitis sicca in a woman with anticentromere antibodies. Eur. J. Intern. Med. 17: 360-362 (2006).

• Tucker LE. Primary biliary cirrhosis: current diagnosis and treatment. Gastroenterol. Nurs. 15: 70-76 (1992).

• Turner IB, Rawlins MD, Wood P, James OF. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment. Pharmacol. Ther. 8: 337-342 (1994).

• Twaddell WS, Lefkowitch J, Berk PD. Evolution from primary biliary cirrhosis to primary biliary cirrhosis/autoimmune hepatitis overlap syndrome. Semin. Liver Dis. 28: 128-134 (2008).

• Uddenfeldt P, Bjerle P, Danielsson A, Nystrom L, Stjernberg N. Lung function abnormalities in patients with primary biliary cirrhosis. Acta Med. Scand. 223: 549-555 (1988).

• Umeuchi H, Kawashima Y, Aoki CA, Kurokawa T, Nakao K, Itoh M, Kikuchi K, Kato T, Okano K, Gershwin ME, Miyakawa H. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride. Eur. J. Pharmacol. 518: 133-139 (2005). *

• Valdes AMD, Schroeder HF, Roizen GV, Honeyman MJ, Sanchez ML. Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade(R)). Rev. Med. Chil. 134: 326-331 (2006).

• van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC. Interleukin-17 in inflammatory skin disorders. Curr. Opin. Allergy Clin. Immunol. 7: 374-381 (2007). *

• Van Bodegraven AA, Pena AS. Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 201-212 (2003).

• Van Buuren HR, Vleggaar FP, Willemien Erkelens G, Zondervan PE, Lesterhuis W, Van Eijck CH, Puylaert JB, Van Der Werf SD. Autoimmune pancreatocholangitis: a series of ten patients. Scand. J. Gastroenterol. Suppl. 243: 70-78 (2006). *

• van de Meeberg PC, Houwen RH, Sinaasappel M, Heijerman HG, Bijleveld CM, Vanberge-Henegouwen GP. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand. J. Gastroenterol. 32: 369-373 (1997).

• van Hoogstraten HJ, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, van Hattum J, van Berge Henegouwen GP, Schalm SW, van Buuren HR. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am. J. Gastroenterol. 95: 2015-2022 (2000). *

• van Mil SW, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuk V, Moore GE, Lammert F, Glantz AG, Mattsson LA, Whittaker J, Parker MG, White R, Williamson C. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133: 507-516 (2007). *

• van Milligen de Wit AW, van Bracht J, Rauws EA, Jones EA, Tytgat GN, Huibregtse K. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest. Endosc. 44: 293-299 (1996).

• Vankeerberghen L, Oppenheimer M, Opolon P, Levy VG. Treatment of intra-heptic cholestasis in primary biliary cirrhosis by long term plasmapheresis. Life Support Syst. 1 Suppl. 1: 106-111 (1983).

• Vazquez Calatayud M, Carrion Torre M, Garcia-Fernandez N. MARS(R) (Molecular Adsorbents Recirculating System). New technique of extracorporeal depuration in liver failure. Enferm. Intensiva 16: 119-126 (2005).

• Velayudham LS, Farrell GC. Drug-induced cholestasis. Expert Opin. Drug Saf. 2: 287-304 (2003).

• Velicia Llames MR, Gonzalez Hernandez JM, Fernandez Orcajo P, Sanz Santacruz C. Symptomatic primary biliary stenosis without cholestasis. Gastroenterol. Hepatol. 18: 330-331 (1995).

• Vere CC, Gofita E, Fortofoiu C, Streba LA, Genunche A. Antiviral therapy effects upon hepatitis C cholestatic syndrome. Rom. J. Morphol. Embryol. 48: 51-54 (2007).

• Verma A, Jazrawi RP, Ahmed HA, Davis T, Bland JM, Benson M, Orchard RT, Theodossi A, Maxwell JD, Northfield TC. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 11: 1069-1076 (1999).

• Vlachogiannakos J, Carpenter J, Goulis J, Triantos C, Patch D, Burroughs AK. Variceal bleeding in primary biliary cirrhosis patients: a subgroup with improved prognosis and a model to predict survival after first bleeding. Eur. J. Gastroenterol. Hepatol. 21: 701-707 (2009).

• Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur. J. Gastroenterol. Hepatol. 20: 688-692 (2008). *

• Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, Hop WC, van Erpecum KJ. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur. J. Gastroenterol. Hepatol. 13: 171-175 (2001).

• Vleggaar FP, van Buuren HR, Zondervan PE, ten Kate FJ, Hop WC; Dutch Multicentre PBC study group. Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut 49: 276-281 (2001). *

• Vuoristo M, Farkkila M, Karvonen AL, Leino R, Lehtola J, Makinen J, Mattila J, Friman C, Seppala K, Tuominen J, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 108: 1470-1478 (1995). *

• Wagle SD, Jagtap SP, Wadia F. Primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Indian J. Gastroenterol. 23: 70-71 (2004). *

• Wang J, Jiang W, Gao H, He B, Liu W. Clinical and pathological characteristics of primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 10: 334-337 (2002).

• Wang JS, Wang XH, Zhu QR, Wang ZL, Hu XQ, Zheng S. Clinical and pathological characteristics of Alagille syndrome in Chinese children. World J. Pediatr. 4: 283-288 (2008). *

• Wang XD, Yao Q, Peng B, Zhang L, Ai Y, Ying AY, Liu XH, Liu SY. A clinical analysis of intrahepatic cholestasis of pregnancy in 1241 cases. Zhonghua Gan Zang Bing Za Zhi 15: 291-293 (2007).

• Wanty C, Joomye R, Van Hoorebeek N, Paul K, Otte JB, Reding R, Sokal EM. Fifteen years single center experience in the management of progressive familial intrahepatic cholestasis of infancy. Acta Gastroenterol. Belg. 67: 313-319 (2004).

• Warren JE, Blaylock RC, Silver RM. Plasmapheresis for the treatment of intrahepatic cholestasis of pregnancy refractory to medical treatment. Am. J. Obstet. Gynecol. 192: 2088-2089 (2005). *

• Wasmuth HE, Glantz A, Keppeler H, Simon E, Bartz C, Rath W, Mattsson LA, Marschall HU, Lammert F. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter gene ABCB4. Gut 56: 265-270 (2007). *

• Wei LX, Floriani A, Variola A, El Younis C, Bergasa NV. A study of the Mu opioid receptor gene polymorphism A118G in patients with primary biliary cirrhosis with and without pruritus. Acta Derm. Venereol. 88: 323-326 (2008).

• Weindl G, Roeder A, Schafer-Korting M, Schaller M, Korting HC. Receptor-selective retinoids for psoriasis: focus on tazarotene. Am. J. Clin. Dermatol. 7: 85-97 (2006).

• Weisshaar E, Seeliger S, Diepgen TL, Luger TA, Stander S. Pruritus in childhood. A diagnostic and therapeutic challenge. Hautarzt. 55: 855-868 (2004).

• Weldon D. What lies beneath the surface of the itch in adults? Allergy Asthma Proc. 28: 153-162 (2007).

• Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15: 465-489 (2001).

• Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med. J. Aust. 177: 440-443 (2002).

• Whitington PF, Freese DK, Alonso EM, Schwarzenberg SJ, Sharp HL. Clinical and biochemical findings in progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 18: 134-141 (1994).

• Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 95: 130-136 (1988).

• Whitmore SE. Treatment of hepatobiliary pruritus. J. Am. Acad. Dermatol. 36: 279 (1997).

• Wiesner RH, LaRusso NF, Ludwig J, Dickson ER. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 88: 108-114 (1985).

• Wiesner RH, Ludwig J, Lindor KD, Jorgensen RA, Baldus WP, Homburger HA, Dickson ER. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N. Engl. J. Med. 322: 1419-1424 (1990).

• Wiesner RH, Porayko MK, Hay JE, LaRusso NF, Steers JL, Krom RA, Dickson ER. Liver transplantation for primary sclerosing cholangitis: impact of risk factors on outcome. Liver Transpl. Surg. 2: 99-108 (1996).

• Wietholtz H, Marschall HU, Sjovall J, Matern S. Stimulation of bile acid 6 alpha-hydroxylation by rifampin. J. Hepatol. 24: 713-718 (1996). *

• Wolf R, Krakowski A. Variations in aquagenic pruritus and treatment alternatives. J. Am. Acad. Dermatol. 18: 1081-1083 (1988).

• Wolfhagen FH, Engelkens HJ, van Buuren HR. The pathophysiology and treatment of cholestatic pruritus. Ned. Tijdschr. Geneeskd. 142: 688-692 (1998).

• Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 113: 1264-1269 (1997). *

• Wolfhagen FH, van Buuren HR, Schalm SW. Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis. Neth. J. Med. 44: 84-90 (1994).

• Wolfhagen FH, van Hoogstraten HJ, van Buuren HR, van Berge-Henegouwen GP, ten Kate FJ, Hop WC, van der Hoek EW, Kerbert MJ, van Lijf HH, den Ouden JW, Smit AM, de Vries RA, van Zanten RA, Schalm SW. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J. Hepatol. 29: 736-742 (1998). *

• Wolfhagen FH, Vermeulen HG, de Man RA, Lesterhuis W. Initially obscure hepatotoxicity attributed to sildenafil. Eur. J. Gastroenterol. Hepatol. 20: 710-712 (2008).

• Wolkenstein P. Living with psoriasis. J. Eur. Acad. Dermatol. Venereol. 20 Suppl. 2: 28-32 (2006).

• Wollenschlager I, Hermann J, Ockenfels HM. Targeted UVB-308 nm (NUVB) therapy with excimer laser in the treatment of atopic dermatitis and other inflammatory dermatoses. Hautarzt. 60: 898-906 (2009).

• Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am. J. Clin. Dermatol. 8: 157-173 (2007).

• Wollina U, Hansel G, Koch A, Abdel-Naser MB. Topical pimecrolimus for skin disease other than atopic dermatitis. Expert Opin. Pharmacother. 7: 1967-1975 (2006).

• Wong LF, Shallow H, O'Connell MP. Comparative study on the outcome of obstetric cholestasis. J. Matern. Fetal Neonatal Med. 21: 327-330 (2008).

• Wong RK, Lim SG, Wee A, Chan YH, Aung MO, Wai CT. Primary biliary cirrhosis in Singapore: evaluation of demography, prognostic factors and natural course in a multi-ethnic population. J. Gastroenterol. Hepatol. 23: 599-605 (2008). *

• Woo TY. Systemic isotretinoin treatment of oral and cutaneous lichen planus. Cutis 35: 385-386, 390-391, 393 (1985).

• Woodward DF, Nieves AL, Friedlaender MH. Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching. J. Pharmacol. Exp. Ther. 279: 137-142 (1996).

• Wooldridge WE. Dermatologic symptoms without signs. Seeking the cause of itching, pain, and burning. Postgrad. Med. 85: 369-70, 375 (1989).

• Woolf GM, Reynolds TB. Failure of rifampin to relieve pruritus in chronic liver disease. J. Clin. Gastroenterol. 12: 174-177 (1990).

• Worthington J, Chapman R. Primary sclerosing cholangitis. Orphanet J. Rare Dis. 1: 41 (2006). *

• Yang H, Porte RJ, Verkade HJ, De Langen ZJ, Hulscher JB. Partial external biliary diversion in children with progressive familial intrahepatic cholestasis and Alagille disease. J. Pediatr. Gastroenterol. Nutr. 49: 216-221 (2009).

• Yao D, Xie W, Wang L. Clinical analysis of 22 patients with primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 10: 344-345 (2002).

• Yao Y, Xu ZY, Gao JP, Chen XP, Shen LJ, Yang LH, You LY, Yang JH. Liver histopathology, clinical features and prognostic factors of primary biliary cirrhosis: an analysis of 60 cases. Zhonghua Gan Zang Bing Za Zhi 16: 457-460 (2008).

• Yap I, Wee A, Tay HH, Guan R, Kang JY. Primary biliary cirrhosis - an uncommon disease in Singapore. Singapore Med. J. 37: 48-50 (1996).

• Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Karrer FM. Use of rifampin for severe pruritus in children with chronic cholestasis. J. Pediatr. Gastroenterol. Nutr. 29: 442-447 (1999). *

• Yoon JH, Gores GJ. Diagnosis, staging, and treatment of cholangiocarcinoma. Curr. Treat. Options Gastroenterol. 6: 105-112 (2003).

• Yoong W, Memtsa M, Pun S, West P, Loo C, Okolo S. Pregnancy outcomes of women with pruritus, normal bile salts and liver enzymes: a case control study. Acta Obstet. Gynecol. Scand. 87: 419-422 (2008).

• Yosipovitch G. The pruritus receptor unit: a target for novel therapies. J. Invest. Dermatol. 127: 1857-1859 (2007). *

• Yosipovitch G, Fleischer A. Itch associated with skin disease: advances in pathophysiology and emerging therapies. Am. J. Clin. Dermatol. 4: 617-622 (2003).

• Zachariae R, Zachariae CO, Lei U, Pedersen AF. Affective and sensory dimensions of pruritus severity: associations with psychological symptoms and quality of life in psoriasis patients. Acta Derm. Venereol. 88: 121-127 (2008).

• Zampeli E, Tiligada E. The role of histamine H(4) receptor in immune and inflammatory disorders. Br. J. Pharmacol. 157: 24-33 (2009).

• Zapata R, Sandoval L, Palma J, Hernandez I, Ribalta J, Reyes H, Sedano M, Toha D, Silva JJ. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Liver Int. 25: 548-554 (2005). *

• Zhang F, Jia J, Cui R, Wang B, Wang H. Clinical features of forty patients with primary biliary cirrhosis. Chin. Med. J. (Engl.) 115: 904-908 (2002).

• Zhang F, Jia J, Wang B, Qian L, Yin S, Wang Y, Cui Y, You H, Ma H, Wang H, Zhang C. Clinical characteristics of primary biliary cirrhosis: a report of 45 cases. Zhonghua Nei Ke Za Zhi 41: 163-167 (2002).

• Zimmerman HJ, Lewis JH. Drug-induced cholestasis. Med. Toxicol. 2: 112-160 (1987).

• Zimmermann K, Cueni B, Schmid M. Combined form of chronic aggressive hepatitis primary biliary cirrhosis. Schweiz. Med. Wochenschr. 107: 1749-1752 (1977).

• Zirwas MJ, Seraly MP. Pruritus of unknown origin: a retrospective study. J. Am. Acad. Dermatol. 45: 892-896 (2001).

• Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br. J. Pharmacol. 156: 7-27 (2009). *

• Zuber J, Bellanne-Chantelot C, Carette C, Canaud G, Gobrecht S, Gaha K, Mallet V, Martinez F, Thervet E, Timsit J, Legendre C, Dubois-Laforgue D. HNF1B-related diabetes triggered by renal transplantation. Nat. Rev. Nephrol. 5: 480-484 (2009).

• Zuccati G, Lotti T, Mastrolorenzo A, Rapaccini A, Tiradritti L. Pruritus ani. Dermatol. Ther. 18: 355-362 (2005).

Number of references = 857

www psc-literature.org